_pmid,_doi,_publicationTitle,_year,_confidence,_toolType,resourceName,resourceType,rrid,synonyms,description,aiSummary,howToAcquire,_resourceName
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,animal_model,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,Animal Model,,,,,,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,Fiber Photometry Trace Processing,Computational Tool,,,,,,Fiber Photometry Trace Processing
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,genetic_reagent,dLight1,Genetic Reagent,,,,,,dLight1
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,Novoalign tool v3.02.06,Computational Tool,,,,,,Novoalign tool v3.02.06
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,PICARD tools v2.4.1,Computational Tool,,,,,,PICARD tools v2.4.1
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,Genome Analysis Toolkit (GATK) v3.6-0,Computational Tool,,,,,,Genome Analysis Toolkit (GATK) v3.6-0
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,Mutect v1.1.4,Computational Tool,,,,,,Mutect v1.1.4
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,computational_tool,SciClone,Computational Tool,,,,,,SciClone
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,cell_line,NPcis cell line,Cell Line,,,,,,NPcis cell line
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.95,clinical_assessment_tool,Survey of Well-being of Young Children (SWYC),Clinical Assessment Tool,,,,,,Survey of Well-being of Young Children (SWYC)
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,computational_tool,LMSz,Computational Tool,,,,,,LMSz
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,computational_tool,gamlssTools,Computational Tool,,,,,,gamlssTools
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,clinical_assessment_tool,Centers for Disease Control (CDC) growth charts,Clinical Assessment Tool,,,,,,Centers for Disease Control (CDC) growth charts
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,animal_model,Nf1 flox/flox ; Hoxb7-Cre mice,Animal Model,,,,,,Nf1 flox/flox ; Hoxb7-Cre mice
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,animal_model,Nf1 f/neo ; hGFAP-Cre mice,Animal Model,,,,,,Nf1 f/neo ; hGFAP-Cre mice
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,cell_line,BJFF.6,Cell Line,,,,,,BJFF.6
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,cell_line,Normal human Schwann cells (Sciencell),Cell Line,,,,,,Normal human Schwann cells (Sciencell)
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,GFAP,Antibody,,,,,,GFAP
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Iba1,Antibody,,,,,,Iba1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Ki67,Antibody,,,,,,Ki67
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,SOX10,Antibody,,,,,,SOX10
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Rbpms,Antibody,,,,,,Rbpms
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Tuj-1,Antibody,,,,,,Tuj-1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Peripherin,Antibody,,,,,,Peripherin
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,ISL1,Antibody,,,,,,ISL1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,computational_tool,AXION Biosystems integrated studio (AxIS) version 2.5.1,Computational Tool,,,,,,AXION Biosystems integrated studio (AxIS) version 2.5.1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,computational_tool,Offline sorter x64 version 4,Computational Tool,,,,,,Offline sorter x64 version 4
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,computational_tool,ImageJ 1.53a,Computational Tool,,,,,,ImageJ 1.53a
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,computational_tool,"Partek Flow software, version 10.0",Computational Tool,,,,,,"Partek Flow software, version 10.0"
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,computational_tool,STAR version 2.7.8a,Computational Tool,,,,,,STAR version 2.7.8a
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,cell_line,TOP-10F' cells,Cell Line,,,,,,TOP-10F' cells
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,computational_tool,Splice Site Prediction by Neural Network (SSPNN),Computational Tool,,,,,,Splice Site Prediction by Neural Network (SSPNN)
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.95,computational_tool,mfold computer program version 3.0,Computational Tool,,,,,,mfold computer program version 3.0
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,DhhCre,Animal Model,,,,,,DhhCre
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,computational_tool,Prism7 (GraphPad),Computational Tool,,,,,,Prism7 (GraphPad)
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,cell_line,MCF7,Cell Line,,,,,,MCF7
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,Agilent Seahorse XF-96,Computational Tool,,,,,,Agilent Seahorse XF-96
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,STAR v2.7.8a,Computational Tool,,,,,,STAR v2.7.8a
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,iDEP 9.1,Computational Tool,,,,,,iDEP 9.1
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,Trim Galore v0.6.0,Computational Tool,,,,,,Trim Galore v0.6.0
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,advanced_cellular_model,Matrigel spheroids,Advanced Cellular Model,,,,,,Matrigel spheroids
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,LipidSearch v5.0,Computational Tool,,,,,,LipidSearch v5.0
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,Compound Discoverer v3.2,Computational Tool,,,,,,Compound Discoverer v3.2
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,SynergyFinder R package,Computational Tool,,,,,,SynergyFinder R package
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,CEAS R Package,Computational Tool,,,,,,CEAS R Package
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,FactoMineR R package,Computational Tool,,,,,,FactoMineR R package
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,cell_line,human retinal ganglion cells (hRGC),Cell Line,,,,,,human retinal ganglion cells (hRGC)
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,National Institute of Health diagnostic criteria for NF1,Clinical Assessment Tool,,,,,,National Institute of Health diagnostic criteria for NF1
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.8,clinical_assessment_tool,P300 event-related potential,Clinical Assessment Tool,,,,,,P300 event-related potential
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.75,clinical_assessment_tool,WM nback task,Clinical Assessment Tool,,,,,,WM nback task
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.85,clinical_assessment_tool,P.L.E.A.S.E.® device,Clinical Assessment Tool,,,,,,P.L.E.A.S.E.® device
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Dermlite DL3,Clinical Assessment Tool,,,,,,Dermlite DL3
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,NIH Consensus Development Conference NF1 diagnostic criteria,Clinical Assessment Tool,,,,,,NIH Consensus Development Conference NF1 diagnostic criteria
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,,FlowJo software
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,computational_tool,Orbitrap Fusion Lumos mass spectrometer,Computational Tool,,,,,,Orbitrap Fusion Lumos mass spectrometer
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,,ImageJ software
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.95,cell_line,Primary Schwannoma Cells,Cell Line,,,,,,Primary Schwannoma Cells
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,animal_model,2.3-kb α1(I) collagen-cre Nf1 flox/flox mice,Animal Model,,,,,,2.3-kb α1(I) collagen-cre Nf1 flox/flox mice
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,animal_model,Nf1 flox/flox mice,Animal Model,,,,,,Nf1 flox/flox mice
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,cell_line,Nf1 flox/flox calvaria osteoblasts,Cell Line,,,,,,Nf1 flox/flox calvaria osteoblasts
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,DH10Bac cells,Cell Line,,,,,,DH10Bac cells
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,BL21(DE3),Cell Line,,,,,,BL21(DE3)
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,Sf9 cells,Cell Line,,,,,,Sf9 cells
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,Tni-FNL cells,Cell Line,,,,,,Tni-FNL cells
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.95,cell_line,NF1-null HEK293T cell line,Cell Line,,,,,,NF1-null HEK293T cell line
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,HEK293T,Cell Line,,,,,,HEK293T
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,SEDFIT 16.1,Computational Tool,,,,,,SEDFIT 16.1
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,SEDPHAT 14.0,Computational Tool,,,,,,SEDPHAT 14.0
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,EMAN2 e2boxer,Computational Tool,,,,,,EMAN2 e2boxer
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,Sphire,Computational Tool,,,,,,Sphire
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,Relion,Computational Tool,,,,,,Relion
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,MantidPlot,Computational Tool,,,,,,MantidPlot
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,ATSAS,Computational Tool,,,,,,ATSAS
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,animal_model,Nf1 flox,Animal Model,,,,,,Nf1 flox
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,STAR 2.4.2a,Computational Tool,,,,,,STAR 2.4.2a
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,GSEA software 4.0.1,Computational Tool,,,,,,GSEA software 4.0.1
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,DAVID 6.8,Computational Tool,,,,,,DAVID 6.8
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,MaxQuant (v1.5.3.30),Computational Tool,,,,,,MaxQuant (v1.5.3.30)
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,computational_tool,AxioVision 4.6 software,Computational Tool,,,,,,AxioVision 4.6 software
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,BWA-MEM,Computational Tool,,,,,,BWA-MEM
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,manta,Computational Tool,,,,,,manta
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Pindel,Computational Tool,,,,,,Pindel
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,GenVisR,Computational Tool,,,,,,GenVisR
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,COSMIC,Computational Tool,,,,,,COSMIC
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,ClinVar,Computational Tool,,,,,,ClinVar
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,SIFT,Computational Tool,,,,,,SIFT
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Polyphen,Computational Tool,,,,,,Polyphen
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,SciClone,Computational Tool,,,,,,SciClone
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,ClonEvol,Computational Tool,,,,,,ClonEvol
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Partek Flow,Computational Tool,,,,,,Partek Flow
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,gplots,Computational Tool,,,,,,gplots
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,PantherDB,Computational Tool,,,,,,PantherDB
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,cell_line,S462TY,Cell Line,,,,,,S462TY
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,cell_line,iSC,Cell Line,,,,,,iSC
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.85,cell_line,A549,Cell Line,,,,,,A549
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.85,cell_line,MCF10A,Cell Line,,,,,,MCF10A
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,computational_tool,CompuSyn software Version 1.0,Computational Tool,,,,,,CompuSyn software Version 1.0
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,computational_tool,IBM SPSS Statistics software version 29.0.1.0,Computational Tool,,,,,,IBM SPSS Statistics software version 29.0.1.0
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,computational_tool,SPIN (Signal Processing in MR Version SVN Revision 1895),Computational Tool,,,,,,SPIN (Signal Processing in MR Version SVN Revision 1895)
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,BWA-MEM,Computational Tool,,,,,,BWA-MEM
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,VarDict,Computational Tool,,,,,,VarDict
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,Manta,Computational Tool,,,,,,Manta
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,SvABA,Computational Tool,,,,,,SvABA
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,MuSE,Computational Tool,,,,,,MuSE
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,MSIprofiler,Computational Tool,,,,,,MSIprofiler
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,FACETS,Computational Tool,,,,,,FACETS
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ascatNGS,Computational Tool,,,,,,ascatNGS
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ShatterSeek,Computational Tool,,,,,,ShatterSeek
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,TopHat-fusion,Computational Tool,,,,,,TopHat-fusion
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,EricScript,Computational Tool,,,,,,EricScript
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,minfi,Computational Tool,,,,,,minfi
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,,ConsensusClusterPlus
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,IchorCNA,Computational Tool,,,,,,IchorCNA
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,survival,Computational Tool,,,,,,survival
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.9,computational_tool,GraphPad Prism version 6.0h,Computational Tool,,,,,,GraphPad Prism version 6.0h
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,advanced_cellular_model,primary cultures derived from plexiform neurofibromas,Advanced Cellular Model,,,,,,primary cultures derived from plexiform neurofibromas
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,computational_tool,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",Computational Tool,,,,,,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)"
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,cell_line,ipNF 95.11b,Cell Line,,,,,,ipNF 95.11b
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,cell_line,ipn 02.8,Cell Line,,,,,,ipn 02.8
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,computational_tool,ImageJ (v1.53a),Computational Tool,,,,,,ImageJ (v1.53a)
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,computational_tool,NIH ImageJ (version 1.53a),Computational Tool,,,,,,NIH ImageJ (version 1.53a)
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,computational_tool,DNA Engine Peltier Thermal cycler (PTC-200),Computational Tool,,,,,,DNA Engine Peltier Thermal cycler (PTC-200)
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.95,computational_tool,"ABI Prism 7,000 Sequence Detection System",Computational Tool,,,,,,"ABI Prism 7,000 Sequence Detection System"
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,computational_tool,Simpleware ScanIP,Computational Tool,,,,,,Simpleware ScanIP
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.9,computational_tool,DPP V1.0,Computational Tool,,,,,,DPP V1.0
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,computational_tool,Simpleware,Computational Tool,,,,,,Simpleware
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Numerical Rating Scale-11,Clinical Assessment Tool,,,,,,Numerical Rating Scale-11
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Brief Pain Inventory Pain Interference subscale,Clinical Assessment Tool,,,,,,Brief Pain Inventory Pain Interference subscale
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Pediatric Quality of Life Inventory NF1 module,Clinical Assessment Tool,,,,,,Pediatric Quality of Life Inventory NF1 module
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,computational_tool,Phoenix WinNonlin (Version 8.1),Computational Tool,,,,,,Phoenix WinNonlin (Version 8.1)
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,computational_tool,NONMEM (version 7.2),Computational Tool,,,,,,NONMEM (version 7.2)
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,computational_tool,Perl speaks NONMEM version 3.6.2,Computational Tool,,,,,,Perl speaks NONMEM version 3.6.2
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,computational_tool,Pirana version 2.7.1,Computational Tool,,,,,,Pirana version 2.7.1
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,computational_tool,SAS version 9.4,Computational Tool,,,,,,SAS version 9.4
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.95,clinical_assessment_tool,cNF-Skindex,Clinical Assessment Tool,,,,,,cNF-Skindex
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,clinical_assessment_tool,EQ-5D-5L,Clinical Assessment Tool,,,,,,EQ-5D-5L
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,clinical_assessment_tool,SF-36,Clinical Assessment Tool,,,,,,SF-36
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.8,computational_tool,SPSS version 28.0,Computational Tool,,,,,,SPSS version 28.0
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.95,clinical_assessment_tool,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),Clinical Assessment Tool,,,,,,World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,clinical_assessment_tool,Relaxation Response Resiliency Program for NF (3RP-NF),Clinical Assessment Tool,,,,,,Relaxation Response Resiliency Program for NF (3RP-NF)
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,clinical_assessment_tool,Health Enhancement Program for NF (HEP-NF),Clinical Assessment Tool,,,,,,Health Enhancement Program for NF (HEP-NF)
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.8,computational_tool,REDCap,Computational Tool,,,,,,REDCap
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,computational_tool,"SAS, version 9.4",Computational Tool,,,,,,"SAS, version 9.4"
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.9,computational_tool,www.synapse.org/SynodosNF2,Computational Tool,,,,,,www.synapse.org/SynodosNF2
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.9,cell_line,murine NF2 −/− Schwann cell line,Cell Line,,,,,,murine NF2 −/− Schwann cell line
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.9,cell_line,HEI-193,Cell Line,,,,,,HEI-193
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,clinical_assessment_tool,DPOAE,Clinical Assessment Tool,,,,,,DPOAE
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,clinical_assessment_tool,ABR,Clinical Assessment Tool,,,,,,ABR
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,hind-limb clasping test,Clinical Assessment Tool,,,,,,hind-limb clasping test
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,ledge test,Clinical Assessment Tool,,,,,,ledge test
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,rotarod assay,Clinical Assessment Tool,,,,,,rotarod assay
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,cell_line,p53−/− mouse embryonic liver progenitor cells,Cell Line,,,,,,p53−/− mouse embryonic liver progenitor cells
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,FastQC (version 0.11.2),Computational Tool,,,,,,FastQC (version 0.11.2)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,Bowtie (version 1.0.0),Computational Tool,,,,,,Bowtie (version 1.0.0)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,BWA version 0.7.5,Computational Tool,,,,,,BWA version 0.7.5
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,SAMtools (version 0.1.19),Computational Tool,,,,,,SAMtools (version 0.1.19)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,VarScan2 (version 2.3),Computational Tool,,,,,,VarScan2 (version 2.3)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,STAR (version 2.3.0e),Computational Tool,,,,,,STAR (version 2.3.0e)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,DESeq (version 1.18.0),Computational Tool,,,,,,DESeq (version 1.18.0)
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,cell_line,293fs cells,Cell Line,,,,,,293fs cells
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,WGCNA,Computational Tool,,,,,,WGCNA
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,,ConsensusClusterPlus
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF05.5 (mixed clone),Cell Line,,,,,,ipNF05.5 (mixed clone)
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF05.5 (single clone),Cell Line,,,,,,ipNF05.5 (single clone)
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF95.11bC,Cell Line,,,,,,ipNF95.11bC
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF95.6,Cell Line,,,,,,ipNF95.6
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipnNF95.11c,Cell Line,,,,,,ipnNF95.11c
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,Mechanism Interrogation PlatE (MIPE 4.0) library,Computational Tool,,,,,,Mechanism Interrogation PlatE (MIPE 4.0) library
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,IDAPredict.2drug function package,Computational Tool,,,,,,IDAPredict.2drug function package
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,Dermus SkinScanner,Clinical Assessment Tool,,,,,,Dermus SkinScanner
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.9,animal_model,y w Mer4,Animal Model,,,,,,y w Mer4
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,animal_model,4/FM7; T80-Gal4 y w Mer4,Animal Model,,,,,,4/FM7; T80-Gal4 y w Mer4
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Barocycler NEP 2320,Computational Tool,,,,,,Barocycler NEP 2320
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Easy-nLC 1200,Computational Tool,,,,,,Easy-nLC 1200
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Q Exactive HF mass spectrometer,Computational Tool,,,,,,Q Exactive HF mass spectrometer
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,Thermo Xcalibur 4.1,Computational Tool,,,,,,Thermo Xcalibur 4.1
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,Spectronaut Pulsar,Computational Tool,,,,,,Spectronaut Pulsar
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,BenchMark Ultra system,Computational Tool,,,,,,BenchMark Ultra system
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,NanoZoomer S60 digital slide scanner,Computational Tool,,,,,,NanoZoomer S60 digital slide scanner
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Pannoramic Midi FL slide scanner,Computational Tool,,,,,,Pannoramic Midi FL slide scanner
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,R software version 4.0.0,Computational Tool,,,,,,R software version 4.0.0
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,lmerTest package version 3.1-2,Computational Tool,,,,,,lmerTest package version 3.1-2
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.95,animal_model,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice,Animal Model,,,,,,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,animal_model,Nf1flox mice,Animal Model,,,,,,Nf1flox mice
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,computational_tool,AxioVision 4.1 software,Computational Tool,,,,,,AxioVision 4.1 software
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,computational_tool,analySIS 5.0 software,Computational Tool,,,,,,analySIS 5.0 software
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,animal_model,Nf1flox/flox,Animal Model,,,,,,Nf1flox/flox
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,animal_model,Nf1GFAP CKO,Animal Model,,,,,,Nf1GFAP CKO
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,computational_tool,Gel-Pro Analyzer 4.0,Computational Tool,,,,,,Gel-Pro Analyzer 4.0
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,computational_tool,GraphPad Prism 4.0,Computational Tool,,,,,,GraphPad Prism 4.0
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,computational_tool,NextGENe software v.2.3.4.1,Computational Tool,,,,,,NextGENe software v.2.3.4.1
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,cell_line,HEK-293T cells,Cell Line,,,,,,HEK-293T cells
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,,ImageJ software
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,cell_line,HEK 293T,Cell Line,,,,,,HEK 293T
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.95,cell_line,immortalized mouse Nf2 Schwann cells,Cell Line,,,,,,immortalized mouse Nf2 Schwann cells
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,computational_tool,g:Profiler,Computational Tool,,,,,,g:Profiler
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,computational_tool,BioVenn,Computational Tool,,,,,,BioVenn
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,computational_tool,PathVisio software,Computational Tool,,,,,,PathVisio software
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,computational_tool,"Alamut Visual Plus, version 1.5.1",Computational Tool,,,,,,"Alamut Visual Plus, version 1.5.1"
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,cell_line,HEK 293T,Cell Line,,,,,,HEK 293T
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,cell_line,COS-7,Cell Line,,,,,,COS-7
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,animal_model,Nf1 +/− GFAP CKO,Animal Model,,,,,,Nf1 +/− GFAP CKO
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,animal_model,Nf1 flox/flox,Animal Model,,,,,,Nf1 flox/flox
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,antibody,Phosphorylated ERK Thr202/Tyr204 (catalog #4376),Antibody,,,,,,Phosphorylated ERK Thr202/Tyr204 (catalog #4376)
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,Peak Scanner software from Applied Biosystems,Computational Tool,,,,,,Peak Scanner software from Applied Biosystems
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,cell_line,Nf1-/- mouse embryo fibroblasts,Cell Line,,,,,,Nf1-/- mouse embryo fibroblasts
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,cell_line,Nf1+/- mouse embryo fibroblasts,Cell Line,,,,,,Nf1+/- mouse embryo fibroblasts
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,R 2.7.0,Computational Tool,,,,,,R 2.7.0
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,cell_line,T265-2c,Cell Line,,,,,,T265-2c
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,cell_line,90-8,Cell Line,,,,,,90-8
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,computational_tool,Axio Vision Rel. 4.8 software,Computational Tool,,,,,,Axio Vision Rel. 4.8 software
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,computational_tool,Graphpad Prism 6,Computational Tool,,,,,,Graphpad Prism 6
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.95,animal_model,Nf1(flox/-);Col2.3Cre(+) mice,Animal Model,,,,,,Nf1(flox/-);Col2.3Cre(+) mice
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.9,animal_model,Nf1 +/− mice,Animal Model,,,,,,Nf1 +/− mice
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.9,animal_model,Nf1 flox/flox mice,Animal Model,,,,,,Nf1 flox/flox mice
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,piXarray 100 DSR System,Computational Tool,,,,,,piXarray 100 DSR System
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,Computational Tool,,,,,,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,MtestwR software,Computational Tool,,,,,,MtestwR software
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Wechsler Abbreviated Scale of Intelligence (WASI),Clinical Assessment Tool,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Brief Visuospatial Memory Test – Revised (BVMT),Clinical Assessment Tool,,,,,,Brief Visuospatial Memory Test – Revised (BVMT)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Letter‐Number Sequencing task (LNS),Clinical Assessment Tool,,,,,,Letter‐Number Sequencing task (LNS)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,clinical_assessment_tool,Digit Cancellation,Clinical Assessment Tool,,,,,,Digit Cancellation
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Hopkins Verbal Learning Test (HVLT),Clinical Assessment Tool,,,,,,Hopkins Verbal Learning Test (HVLT)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,WISC‐III Object Assembly,Clinical Assessment Tool,,,,,,WISC‐III Object Assembly
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Achenbach Child Behavior Checklist (CBCL),Clinical Assessment Tool,,,,,,Achenbach Child Behavior Checklist (CBCL)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Young Adult Self Report (YASR),Clinical Assessment Tool,,,,,,Young Adult Self Report (YASR)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,clinical_assessment_tool,Neuropsychological Assessment Battery (NAB) Mazes,Clinical Assessment Tool,,,,,,Neuropsychological Assessment Battery (NAB) Mazes
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,Clinical Assessment Tool,,,,,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Behavior Rating Inventory of Executive Function (BRIEF),Clinical Assessment Tool,,,,,,Behavior Rating Inventory of Executive Function (BRIEF)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,clinical_assessment_tool,Spatial capacity working memory (SCAP) task,Clinical Assessment Tool,,,,,,Spatial capacity working memory (SCAP) task
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,computational_tool,FMRIB software library (FSL),Computational Tool,,,,,,FMRIB software library (FSL)
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,Burrows–Wheeler Aligner,Computational Tool,,,,,,Burrows–Wheeler Aligner
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,control-FREEC,Computational Tool,,,,,,control-FREEC
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,RStudio,Computational Tool,,,,,,RStudio
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,APE,Computational Tool,,,,,,APE
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,MEGAX,Computational Tool,,,,,,MEGAX
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,advanced_cellular_model,oviductal organoids,Advanced Cellular Model,,,,,,oviductal organoids
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,advanced_cellular_model,OSE organoids,Advanced Cellular Model,,,,,,OSE organoids
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,cell_line,NF96.2,Cell Line,,,,,,NF96.2
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,cell_line,NF02.2,Cell Line,,,,,,NF02.2
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,cell_line,NF94.3,Cell Line,,,,,,NF94.3
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,computational_tool,XenoBase version 3.5,Computational Tool,,,,,,XenoBase version 3.5
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Affymetrix Expression Console MAS 5.0,Computational Tool,,,,,,Affymetrix Expression Console MAS 5.0
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,computational_tool,StepOne Software v2.3,Computational Tool,,,,,,StepOne Software v2.3
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.85,computational_tool,FSL version 5.0.7,Computational Tool,,,,,,FSL version 5.0.7
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.9,computational_tool,"iPlan Net software (Brainlab, Feldkirchen, Germany)",Computational Tool,,,,,,"iPlan Net software (Brainlab, Feldkirchen, Germany)"
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,computational_tool,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",Computational Tool,,,,,,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)"
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,clinical_assessment_tool,Hannover classification system,Clinical Assessment Tool,,,,,,Hannover classification system
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,clinical_assessment_tool,Koos classification system,Clinical Assessment Tool,,,,,,Koos classification system
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,clinical_assessment_tool,RECIST guidelines,Clinical Assessment Tool,,,,,,RECIST guidelines
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,Haloplex HS,Genetic Reagent,,,,,,Haloplex HS
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,computational_tool,Human Splicing Finder (HSF) Version 2.4.1,Computational Tool,,,,,,Human Splicing Finder (HSF) Version 2.4.1
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,computational_tool,Mutation taster,Computational Tool,,,,,,Mutation taster
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,computational_tool,Combined Annotation Dependent Depletion (CADD) v1.6,Computational Tool,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.95,cell_line,HEK293 cells,Cell Line,,,,,,HEK293 cells
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,Lipofectamine 2000,Genetic Reagent,,,,,,Lipofectamine 2000
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,cell_line,LLC-PK1 ATCC CL-101,Cell Line,,,,,,LLC-PK1 ATCC CL-101
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,computational_tool,CRISPOR,Computational Tool,,,,,,CRISPOR
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,computational_tool,CRISPResso2,Computational Tool,,,,,,CRISPResso2
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.8,computational_tool,JMP Pro 15.0.0,Computational Tool,,,,,,JMP Pro 15.0.0
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,cell_line,HEK 293T,Cell Line,,,,,,HEK 293T
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,computational_tool,CRISPRscan,Computational Tool,,,,,,CRISPRscan
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,computational_tool,Cell Ranger,Computational Tool,,,,,,Cell Ranger
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,computational_tool,Seurat,Computational Tool,,,,,,Seurat
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,MIAPaCa-2,Cell Line,,,,,,MIAPaCa-2
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,Panc-1,Cell Line,,,,,,Panc-1
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,BxPC-3,Cell Line,,,,,,BxPC-3
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,AsPC-1,Cell Line,,,,,,AsPC-1
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,HPDE H6c7,Cell Line,,,,,,HPDE H6c7
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,computational_tool,UN-SCAN-IT gel 6.1,Computational Tool,,,,,,UN-SCAN-IT gel 6.1
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,cell_line,Ben-Men-1,Cell Line,,,,,,Ben-Men-1
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,cell_line,AC-CRISPR,Cell Line,,,,,,AC-CRISPR
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,cell_line,MN1-LF,Cell Line,,,,,,MN1-LF
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,genetic_reagent,V-CSCW2,Genetic Reagent,,,,,,V-CSCW2
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,MM-121,Genetic Reagent,,,,,,MM-121
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,computational_tool,fastQC,Computational Tool,,,,,,fastQC
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,computational_tool,SynergyFinder,Computational Tool,,,,,,SynergyFinder
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.8,cell_line,H358 cells,Cell Line,,,,,,H358 cells
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,cell_line,S462 cells,Cell Line,,,,,,S462 cells
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,cell_line,cis MPNST cell line,Cell Line,,,,,,cis MPNST cell line
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,cell_line,HTS-Luc MPNST cell line,Cell Line,,,,,,HTS-Luc MPNST cell line
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,genetic_reagent,SA3,Genetic Reagent,,,,,,SA3
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,computational_tool,ImageJ Cell Counter extension,Computational Tool,,,,,,ImageJ Cell Counter extension
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.95,clinical_assessment_tool,Tinnitus Functional Index,Clinical Assessment Tool,,,,,,Tinnitus Functional Index
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.9,clinical_assessment_tool,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),Clinical Assessment Tool,,,,,,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE)
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.85,clinical_assessment_tool,Client Oriented Scale of Improvement-Tinnitus,Clinical Assessment Tool,,,,,,Client Oriented Scale of Improvement-Tinnitus
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,CT26,Cell Line,,,,,,CT26
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,U937,Cell Line,,,,,,U937
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,Raji,Cell Line,,,,,,Raji
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,Eμ-ALL,Cell Line,,,,,,Eμ-ALL
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,cell_line,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003),Cell Line,,,,,,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003)
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,computational_tool,R version 3.5.1,Computational Tool,,,,,,R version 3.5.1
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,Brief Symptom Inventory 18 (BSI-18),Clinical Assessment Tool,,,,,,Brief Symptom Inventory 18 (BSI-18)
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,Behavior Problem Index (BPI),Clinical Assessment Tool,,,,,,Behavior Problem Index (BPI)
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,CCSS Neurocognitive Questionnaire,Clinical Assessment Tool,,,,,,CCSS Neurocognitive Questionnaire
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",Clinical Assessment Tool,,,,,,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)"
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,computational_tool,SAS version 9.4,Computational Tool,,,,,,SAS version 9.4
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,computational_tool,R version 3.5.0,Computational Tool,,,,,,R version 3.5.0
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,pNF9511bc,Cell Line,,,,,,pNF9511bc
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,ipNF03.3,Cell Line,,,,,,ipNF03.3
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,ipn023λ,Cell Line,,,,,,ipn023λ
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,cell_line,S462,Cell Line,,,,,,S462
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,RHT92,Cell Line,,,,,,RHT92
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,LN229,Cell Line,,,,,,LN229
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.85,cell_line,2V6.11,Cell Line,,,,,,2V6.11
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,FiPS,Cell Line,,,,,,FiPS
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",Cell Line,,,,,,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12"
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,3PNF_SiPSsv_MM_11,Cell Line,,,,,,3PNF_SiPSsv_MM_11
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,Tuj1,Antibody,,,,,,Tuj1
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,patient_derived_model,JH-2-002,Patient-Derived Model,,,,,,JH-2-002
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,patient_derived_model,JH-2-031,Patient-Derived Model,,,,,,JH-2-031
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,advanced_cellular_model,neurofibromaspheres,Advanced Cellular Model,,,,,,neurofibromaspheres
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M724,Cell Line,,,,,,M724
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,SNF96.2,Cell Line,,,,,,SNF96.2
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,cell_line,HEK-293T,Cell Line,,,,,,HEK-293T
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M1,Cell Line,,,,,,M1
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M3,Cell Line,,,,,,M3
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M4,Cell Line,,,,,,M4
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M5,Cell Line,,,,,,M5
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M6,Cell Line,,,,,,M6
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,genetic_reagent,LentiCRISPR-v2,Genetic Reagent,,,,,,LentiCRISPR-v2
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,computational_tool,Image Studio Lite software,Computational Tool,,,,,,Image Studio Lite software
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.95,computational_tool,DINs (Deep Interactive Networks),Computational Tool,,,,,,DINs (Deep Interactive Networks)
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,computational_tool,3DQI software,Computational Tool,,,,,,3DQI software
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,computational_tool,MEDx software,Computational Tool,,,,,,MEDx software
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,cell_line,Drosophila Schneider (S2R+) cells,Cell Line,,,,,,Drosophila Schneider (S2R+) cells
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,dNF1‐KO,Cell Line,,,,,,dNF1‐KO
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,cell_line,hTERT ipn02.3 2λ CRL‐3392,Cell Line,,,,,,hTERT ipn02.3 2λ CRL‐3392
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipnNF95.11C (hTERT NF1 ipnNF95.11c, RRID: CVCL_UI69)",Cell Line,,,,,,"ipnNF95.11C (hTERT NF1 ipnNF95.11c, RRID: CVCL_UI69)"
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)",Cell Line,,,,,,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)"
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",Cell Line,,,,,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)"
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",Cell Line,,,,,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)"
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,cell_line,ST88‐14 (RRID: CVCL_8916),Cell Line,,,,,,ST88‐14 (RRID: CVCL_8916)
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,animal_model,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,Animal Model,,,,,,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,InVivo 3.2.0 software,Computational Tool,,,,,,InVivo 3.2.0 software
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,Image-Pro Plus software,Computational Tool,,,,,,Image-Pro Plus software
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,"Image J1.45s, version 1.44p",Computational Tool,,,,,,"Image J1.45s, version 1.44p"
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,computational_tool,GraphPad 5 Prism software,Computational Tool,,,,,,GraphPad 5 Prism software
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.85,clinical_assessment_tool,Children's Tumor Foundation NF Registry,Clinical Assessment Tool,,,,,,Children's Tumor Foundation NF Registry
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.9,computational_tool,REDCap,Computational Tool,,,,,,REDCap
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.8,clinical_assessment_tool,5-point Likert-type scales,Clinical Assessment Tool,,,,,,5-point Likert-type scales
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,clinical_assessment_tool,PEERS® intervention,Clinical Assessment Tool,,,,,,PEERS® intervention
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),Clinical Assessment Tool,,,,,,Kaufman Brief Intelligence Test– Second Edition (KBIT-2)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,Clinical Assessment Tool,,,,,,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),Clinical Assessment Tool,,,,,,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Social Communication Questionnaire (SCQ),Clinical Assessment Tool,,,,,,Social Communication Questionnaire (SCQ)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,clinical_assessment_tool,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),Clinical Assessment Tool,,,,,,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Social Responsiveness Scale– Second Edition (SRS-2),Clinical Assessment Tool,,,,,,Social Responsiveness Scale– Second Edition (SRS-2)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Friendship Qualities Scale (FQS),Clinical Assessment Tool,,,,,,Friendship Qualities Scale (FQS)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Quality of Socialization Questionnaire (QSQ),Clinical Assessment Tool,,,,,,Quality of Socialization Questionnaire (QSQ)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Test of Adolescent Social Skills Knowledge (TASSK),Clinical Assessment Tool,,,,,,Test of Adolescent Social Skills Knowledge (TASSK)
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,computational_tool,"IBM SPSS for Windows, version 28",Computational Tool,,,,,,"IBM SPSS for Windows, version 28"
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,computational_tool,GPower 3.1,Computational Tool,,,,,,GPower 3.1
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.8,computational_tool,Burrows-Wheeler Aligner,Computational Tool,,,,,,Burrows-Wheeler Aligner
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,VarDict,Computational Tool,,,,,,VarDict
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,Polyphen2,Computational Tool,,,,,,Polyphen2
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,SIFT,Computational Tool,,,,,,SIFT
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,featureCounts,Computational Tool,,,,,,featureCounts
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,computational_tool,netMHCpan-4.0,Computational Tool,,,,,,netMHCpan-4.0
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,cell_line,U2OS,Cell Line,,,,,,U2OS
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,cell_line,HEK293,Cell Line,,,,,,HEK293
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,clinical_assessment_tool,Pain Interference Index (PII),Clinical Assessment Tool,,,,,,Pain Interference Index (PII)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,clinical_assessment_tool,Pain Interference Index-Parent report (PII-P),Clinical Assessment Tool,,,,,,Pain Interference Index-Parent report (PII-P)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,clinical_assessment_tool,Modified Brief Pain Inventory (MBPI),Clinical Assessment Tool,,,,,,Modified Brief Pain Inventory (MBPI)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,clinical_assessment_tool,Faces Pain Scale-Revised (FPS-R),Clinical Assessment Tool,,,,,,Faces Pain Scale-Revised (FPS-R)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,clinical_assessment_tool,Pain Rating Scale (PRS),Clinical Assessment Tool,,,,,,Pain Rating Scale (PRS)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,clinical_assessment_tool,Pain Rating Scale-Parent version (PRS-P),Clinical Assessment Tool,,,,,,Pain Rating Scale-Parent version (PRS-P)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,clinical_assessment_tool,NF Disease Severity Scale,Clinical Assessment Tool,,,,,,NF Disease Severity Scale
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,clinical_assessment_tool,NF1 Disease Complications Scale,Clinical Assessment Tool,,,,,,NF1 Disease Complications Scale
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.9,computational_tool,CatWalk XT,Computational Tool,,,,,,CatWalk XT
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,,ImageJ software
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.95,cell_line,HEI-193,Cell Line,,,,,,HEI-193
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,cell_line,Epstein-Barr virus-transformed cell lines,Cell Line,,,,,,Epstein-Barr virus-transformed cell lines
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,animal_model,"Trp53, Nf1, Suz12 triple mutant mice",Animal Model,,,,,,"Trp53, Nf1, Suz12 triple mutant mice"
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,genetic_reagent,L-[18F]FETrp,Genetic Reagent,,,,,,L-[18F]FETrp
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,computational_tool,Agilent ChemStation software (version C.01.07),Computational Tool,,,,,,Agilent ChemStation software (version C.01.07)
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,computational_tool,VivoQuant software version 4.0,Computational Tool,,,,,,VivoQuant software version 4.0
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,cell_line,Human meningeal cells (HMC),Cell Line,,,,,,Human meningeal cells (HMC)
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,cell_line,Ben-Men-1 cells,Cell Line,,,,,,Ben-Men-1 cells
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.95,computational_tool,MaxQuant version 1.3.05,Computational Tool,,,,,,MaxQuant version 1.3.05
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,computational_tool,DAVID software,Computational Tool,,,,,,DAVID software
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.85,computational_tool,SYNAPSE,Computational Tool,,,,,,SYNAPSE
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,clinical_assessment_tool,Hematoxylin and eosin (H&E),Clinical Assessment Tool,,,,,,Hematoxylin and eosin (H&E)
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,computational_tool,log-rank Mantel-Cox test,Computational Tool,,,,,,log-rank Mantel-Cox test
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,computational_tool,spatial transcriptomics profiling,Computational Tool,,,,,,spatial transcriptomics profiling
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,clinical_assessment_tool,immunohistochemical staining,Clinical Assessment Tool,,,,,,immunohistochemical staining
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.95,animal_model,Nf1Prx1-/-,Animal Model,,,,,,Nf1Prx1-/-
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,animal_model,Nf1flox/flox,Animal Model,,,,,,Nf1flox/flox
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.9,animal_model,C57BL/6J mice,Animal Model,,,,,,C57BL/6J mice
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,animal_model,Nf1 (+/-) mice,Animal Model,,,,,,Nf1 (+/-) mice
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,cell_line,lymphoblastoid cell lines,Cell Line,,,,,,lymphoblastoid cell lines
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,computational_tool,TRAP (Tiled Regression Analysis Package),Computational Tool,,,,,,TRAP (Tiled Regression Analysis Package)
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,computational_tool,GenomeStudio (v. 2010.2),Computational Tool,,,,,,GenomeStudio (v. 2010.2)
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,animal_model,Nf1flox/flox;PostnCre mice,Animal Model,,,,,,Nf1flox/flox;PostnCre mice
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,clinical_assessment_tool,NRS-11,Clinical Assessment Tool,,,,,,NRS-11
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,clinical_assessment_tool,BPI-PI Scale,Clinical Assessment Tool,,,,,,BPI-PI Scale
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,clinical_assessment_tool,PedsQL NF1 Module,Clinical Assessment Tool,,,,,,PedsQL NF1 Module
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,cell_line,iPNF95.6,Cell Line,,,,,,iPNF95.6
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,MaxQuant (version 1.6.10.43),Computational Tool,,,,,,MaxQuant (version 1.6.10.43)
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,Perseus (version 1.6.10.50),Computational Tool,,,,,,Perseus (version 1.6.10.50)
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,FlowJo Software (version 9.9.6),Computational Tool,,,,,,FlowJo Software (version 9.9.6)
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,ImageJ (version 1.47),Computational Tool,,,,,,ImageJ (version 1.47)
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,HALO Image Analysis Software (version 2.3),Computational Tool,,,,,,HALO Image Analysis Software (version 2.3)
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,clinical_assessment_tool,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),Clinical Assessment Tool,,,,,,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21)
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,animal_model,C57Bl6/J mice,Animal Model,,,,,,C57Bl6/J mice
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,cell_line,OLN93 mouse oligodendrocyte cell line,Cell Line,,,,,,OLN93 mouse oligodendrocyte cell line
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.95,cell_line,SC4-immortalized Nf2-/- primary Schwann cells,Cell Line,,,,,,SC4-immortalized Nf2-/- primary Schwann cells
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,cell_line,RT4-D6PT2 schwannoma cell line,Cell Line,,,,,,RT4-D6PT2 schwannoma cell line
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,cell_line,TC620 human oligodendroglioma cell line,Cell Line,,,,,,TC620 human oligodendroglioma cell line
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,genetic_reagent,pcDNA3.1,Genetic Reagent,,,,,,pcDNA3.1
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,computational_tool,XCELLigence Real Time Cell Analysis System,Computational Tool,,,,,,XCELLigence Real Time Cell Analysis System
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,cell_line,Normal human Schwann cells (NHSC),Cell Line,,,,,,Normal human Schwann cells (NHSC)
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,cell_line,MPNST cell lines,Cell Line,,,,,,MPNST cell lines
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,cell_line,MPNST 88-14 cells,Cell Line,,,,,,MPNST 88-14 cells
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,cell_line,MPNST S462-TY cells,Cell Line,,,,,,MPNST S462-TY cells
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,,FlowJo software
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,computational_tool,Primer 3.0,Computational Tool,,,,,,Primer 3.0
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,antibody,S100,Antibody,,,,,,S100
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,antibody,CD34,Antibody,,,,,,CD34
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,cell_line,S462 cell line,Cell Line,,,,,,S462 cell line
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,cell_line,2884 cell line,Cell Line,,,,,,2884 cell line
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,cell_line,2885 cell line,Cell Line,,,,,,2885 cell line
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,Feature Extraction 10.5,Computational Tool,,,,,,Feature Extraction 10.5
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,Agilent Genomic Workbench 6.5,Computational Tool,,,,,,Agilent Genomic Workbench 6.5
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,Image J software,Computational Tool,,,,,,Image J software
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,advanced_cellular_model,S462 spheres,Advanced Cellular Model,,,,,,S462 spheres
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,hTERT NF1 ipn02.3 2λ,Cell Line,,,,,,hTERT NF1 ipn02.3 2λ
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,ipn95.11bC,Cell Line,,,,,,ipn95.11bC
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,sNF96.2,Cell Line,,,,,,sNF96.2
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,MPNST642,Cell Line,,,,,,MPNST642
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Drop-seq tools (version 1.12),Computational Tool,,,,,,Drop-seq tools (version 1.12)
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Cellranger v5.0.1,Computational Tool,,,,,,Cellranger v5.0.1
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Seurat (version 3.1.0),Computational Tool,,,,,,Seurat (version 3.1.0)
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,computational_tool,scREF,Computational Tool,,,,,,scREF
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,CIBERSORTx,Computational Tool,,,,,,CIBERSORTx
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,inferCNV,Computational Tool,,,,,,inferCNV
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,VECTOR,Computational Tool,,,,,,VECTOR
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Slingshot,Computational Tool,,,,,,Slingshot
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,CytoTRACE version 0.3.3,Computational Tool,,,,,,CytoTRACE version 0.3.3
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,ArchR,Computational Tool,,,,,,ArchR
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,CellChat,Computational Tool,,,,,,CellChat
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,DGIdb (version 3.0.2),Computational Tool,,,,,,DGIdb (version 3.0.2)
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,animal_model,NF1 flox/− mice,Animal Model,,,,,,NF1 flox/− mice
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,cell_line,ipn97.4 immortalized human Schwann cells,Cell Line,,,,,,ipn97.4 immortalized human Schwann cells
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,genetic_reagent,CRISPR Cas9,Genetic Reagent,,,,,,CRISPR Cas9
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Trim Galore (version 0.6.10),Computational Tool,,,,,,Trim Galore (version 0.6.10)
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Broad's Genome Analysis ToolKit (version 4.6.0),Computational Tool,,,,,,Broad's Genome Analysis ToolKit (version 4.6.0)
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,BWA (version 0.7.17-r1188),Computational Tool,,,,,,BWA (version 0.7.17-r1188)
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Picard tools (version 3.2.0),Computational Tool,,,,,,Picard tools (version 3.2.0)
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,Manta,Computational Tool,,,,,,Manta
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,ReAdW v. 3.5.1,Computational Tool,,,,,,ReAdW v. 3.5.1
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,MzXML2Search (included in TPP v. 3.5),Computational Tool,,,,,,MzXML2Search (included in TPP v. 3.5)
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,"Scaffold (Protein Sciences, Portland Oregon)",Computational Tool,,,,,,"Scaffold (Protein Sciences, Portland Oregon)"
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Human Protein Atlas (proteinatlas.org),Computational Tool,,,,,,Human Protein Atlas (proteinatlas.org)
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,QIAGEN Ingenuity Pathway Analysis (IPA),Computational Tool,,,,,,QIAGEN Ingenuity Pathway Analysis (IPA)
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,,FlowJo software
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,genetic_reagent,Gentamicin,Genetic Reagent,,,,,,Gentamicin
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,GraphPad Prism V9,Computational Tool,,,,,,GraphPad Prism V9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,cell_line,Schwann cells,Cell Line,,,,,,Schwann cells
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,animal_model,Nf1fl/fl mice,Animal Model,,,,,,Nf1fl/fl mice
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,animal_model,OPG Nf1fl/mut (Nf1+/−) mice,Animal Model,,,,,,OPG Nf1fl/mut (Nf1+/−) mice
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,cell_line,optic glioma cells,Cell Line,,,,,,optic glioma cells
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Partek Flow software (v.9.0),Computational Tool,,,,,,Partek Flow software (v.9.0)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,STAR (v.2.7.3a),Computational Tool,,,,,,STAR (v.2.7.3a)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,ImageJ (v.2.0.0),Computational Tool,,,,,,ImageJ (v.2.0.0)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Cell Profiler (v.3.1.9),Computational Tool,,,,,,Cell Profiler (v.3.1.9)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Stereo Investigator software (mbfbioscience v2019),Computational Tool,,,,,,Stereo Investigator software (mbfbioscience v2019)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Image Lab software (v.6),Computational Tool,,,,,,Image Lab software (v.6)
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Image Studio Lite (v.5.0.21),Computational Tool,,,,,,Image Studio Lite (v.5.0.21)
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,animal_model,C57BL/6J,Animal Model,,,,,,C57BL/6J
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,computational_tool,origin8.1,Computational Tool,,,,,,origin8.1
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,genetic_reagent,EGFP,Genetic Reagent,,,,,,EGFP
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,genetic_reagent,Lipofectamine,Genetic Reagent,,,,,,Lipofectamine
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,computational_tool,Nikon Elements software,Computational Tool,,,,,,Nikon Elements software
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,BWA-MEM v 0.7.12,Computational Tool,,,,,,BWA-MEM v 0.7.12
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,GATK v3.6.0,Computational Tool,,,,,,GATK v3.6.0
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Mutect V1.1.6,Computational Tool,,,,,,Mutect V1.1.6
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Strelka v1.0.13,Computational Tool,,,,,,Strelka v1.0.13
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,STAR aligner (v.2.6.0),Computational Tool,,,,,,STAR aligner (v.2.6.0)
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,FusionCatcher v1.1.0,Computational Tool,,,,,,FusionCatcher v1.1.0
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,CellRanger,Computational Tool,,,,,,CellRanger
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Seurat version 3.0,Computational Tool,,,,,,Seurat version 3.0
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,inferCNV (v.1.1.1),Computational Tool,,,,,,inferCNV (v.1.1.1)
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,HSC1λ,Cell Line,,,,,,HSC1λ
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,ipNF06.2A,Cell Line,,,,,,ipNF06.2A
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,STS-26T,Cell Line,,,,,,STS-26T
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,S462TY,Cell Line,,,,,,S462TY
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,Nf1 flox/flox,Animal Model,,,,,,Nf1 flox/flox
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,Nf1 +/−,Animal Model,,,,,,Nf1 +/−
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,Nf1 +/− GFAP CKO,Animal Model,,,,,,Nf1 +/− GFAP CKO
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,genetic_reagent,pLKO.1,Genetic Reagent,,,,,,pLKO.1
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,antibody,Tuj-1,Antibody,,,,,,Tuj-1
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,antibody,O4,Antibody,,,,,,O4
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,antibody,GFAP,Antibody,,,,,,GFAP
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,computational_tool,Affymetrix GeneChip Mouse Genome 430 2.0 Array,Computational Tool,,,,,,Affymetrix GeneChip Mouse Genome 430 2.0 Array
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,computational_tool,Partex Genomics Suite Version 6.6 beta,Computational Tool,,,,,,Partex Genomics Suite Version 6.6 beta
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,advanced_cellular_model,optic glioma neurospheres,Advanced Cellular Model,,,,,,optic glioma neurospheres
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,cell_line,TVZ NSCs,Cell Line,,,,,,TVZ NSCs
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,cell_line,iHSC1λ,Cell Line,,,,,,iHSC1λ
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,cell_line,iHSC2λ,Cell Line,,,,,,iHSC2λ
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,S462,Cell Line,,,,,,S462
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,S462-TY,Cell Line,,,,,,S462-TY
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,ST8814,Cell Line,,,,,,ST8814
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,T265,Cell Line,,,,,,T265
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,STS-26T,Cell Line,,,,,,STS-26T
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,pheatmap package,Computational Tool,,,,,,pheatmap package
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,Limma package,Computational Tool,,,,,,Limma package
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,GeneSpring GXv7.3.1,Computational Tool,,,,,,GeneSpring GXv7.3.1
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,CalcuSyn Version 2.1,Computational Tool,,,,,,CalcuSyn Version 2.1
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.85,computational_tool,"Matlab script (Version 9.9.0, Natick, MA)",Computational Tool,,,,,,"Matlab script (Version 9.9.0, Natick, MA)"
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.9,computational_tool,SSTMean,Computational Tool,,,,,,SSTMean
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,hGFAP-cre,Genetic Reagent,,,,,,hGFAP-cre
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.95,genetic_reagent,Nf1 flox,Genetic Reagent,,,,,,Nf1 flox
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,Nf1 KO,Genetic Reagent,,,,,,Nf1 KO
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,Nestin-cre ER,Genetic Reagent,,,,,,Nestin-cre ER
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.85,genetic_reagent,R26 LacZR,Genetic Reagent,,,,,,R26 LacZR
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.95,animal_model,Nf1 hGFAP CKO,Animal Model,,,,,,Nf1 hGFAP CKO
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,animal_model,Nf1 NcreER CKO,Animal Model,,,,,,Nf1 NcreER CKO
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,HeLa cells,Cell Line,,,,,,HeLa cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,MDA-MB-231 cells,Cell Line,,,,,,MDA-MB-231 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,cell_line,S462 cells,Cell Line,,,,,,S462 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,cell_line,PN 04.4 cells,Cell Line,,,,,,PN 04.4 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,4T1 cells,Cell Line,,,,,,4T1 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,CT26 cells,Cell Line,,,,,,CT26 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,RAW 264.7 cells,Cell Line,,,,,,RAW 264.7 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,C2C12 cells,Cell Line,,,,,,C2C12 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,COLO 741 cells,Cell Line,,,,,,COLO 741 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,MEC1 cells,Cell Line,,,,,,MEC1 cells
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,GCAMP6f,Genetic Reagent,,,,,,GCAMP6f
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,mit-Aeqmut,Genetic Reagent,,,,,,mit-Aeqmut
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,GFP-PHD,Genetic Reagent,,,,,,GFP-PHD
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,fastp v.0.2,Computational Tool,,,,,,fastp v.0.2
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,BWA v.0.7.17,Computational Tool,,,,,,BWA v.0.7.17
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,Samtools v.1.7,Computational Tool,,,,,,Samtools v.1.7
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,computational_tool,ichorCNA tool (Broad v.0.2.0),Computational Tool,,,,,,ichorCNA tool (Broad v.0.2.0)
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,deepTools bamPEFragmentSize,Computational Tool,,,,,,deepTools bamPEFragmentSize
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,clinical_assessment_tool,RECIST 1.1,Clinical Assessment Tool,,,,,,RECIST 1.1
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,cell_line,NF1-1 hiPSC line,Cell Line,,,,,,NF1-1 hiPSC line
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,cell_line,NF1-2 hiPSC line,Cell Line,,,,,,NF1-2 hiPSC line
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,cell_line,WT-1 hiPSC line,Cell Line,,,,,,WT-1 hiPSC line
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,cell_line,WT-2 hiPSC line,Cell Line,,,,,,WT-2 hiPSC line
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,computational_tool,CRISPOR software,Computational Tool,,,,,,CRISPOR software
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,,FlowJo software
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,cell_line,HEK293T cells,Cell Line,,,,,,HEK293T cells
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,cell_line,HeLa cells,Cell Line,,,,,,HeLa cells
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,cell_line,LUVA cells,Cell Line,,,,,,LUVA cells
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,computational_tool,AnyMaze software,Computational Tool,,,,,,AnyMaze software
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,computational_tool,ImageJ software,Computational Tool,,,,,,ImageJ software
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,computational_tool,GraphPad Prism version 5.0d,Computational Tool,,,,,,GraphPad Prism version 5.0d
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,3-chamber social preference task,Clinical Assessment Tool,,,,,,3-chamber social preference task
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,Open field test,Clinical Assessment Tool,,,,,,Open field test
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,Delay discounting task,Clinical Assessment Tool,,,,,,Delay discounting task
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,Cliff avoidance reaction test,Clinical Assessment Tool,,,,,,Cliff avoidance reaction test
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,cell_line,U87 glioblastoma cells,Cell Line,,,,,,U87 glioblastoma cells
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,cell_line,sMPNST cells,Cell Line,,,,,,sMPNST cells
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,Origin 8,Computational Tool,,,,,,Origin 8
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,Prism 6.0,Computational Tool,,,,,,Prism 6.0
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.95,clinical_assessment_tool,PedsQL™ NF1 Module,Clinical Assessment Tool,,,,,,PedsQL™ NF1 Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.85,clinical_assessment_tool,PedsQL™ 4.0 Generic Core Scales,Clinical Assessment Tool,,,,,,PedsQL™ 4.0 Generic Core Scales
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Arthritis Module,Clinical Assessment Tool,,,,,,PedsQL™ Arthritis Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Cancer Module,Clinical Assessment Tool,,,,,,PedsQL™ Cancer Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Cerebral Palsy Module,Clinical Assessment Tool,,,,,,PedsQL™ Cerebral Palsy Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Family Impact Module,Clinical Assessment Tool,,,,,,PedsQL™ Family Impact Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,computational_tool,SPSS 18,Computational Tool,,,,,,SPSS 18
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,computational_tool,SAS 9.3,Computational Tool,,,,,,SAS 9.3
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,GFAP,Antibody,,,,,,GFAP
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,OLIG2,Antibody,,,,,,OLIG2
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,SOX10,Antibody,,,,,,SOX10
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,synaptophysin,Antibody,,,,,,synaptophysin
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,p16,Antibody,,,,,,p16
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,ATRX,Antibody,,,,,,ATRX
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,p53,Antibody,,,,,,p53
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,histone H3 K27M mutant protein,Antibody,,,,,,histone H3 K27M mutant protein
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,histone H3 lysine 27 trimethylation,Antibody,,,,,,histone H3 lysine 27 trimethylation
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,Ki-67,Antibody,,,,,,Ki-67
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,UCSF500 NGS Panel,Computational Tool,,,,,,UCSF500 NGS Panel
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,Pindel,Computational Tool,,,,,,Pindel
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,minfi,Computational Tool,,,,,,minfi
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,Rtsne,Computational Tool,,,,,,Rtsne
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,ComplexHeatmap,Computational Tool,,,,,,ComplexHeatmap
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.95,animal_model,Nf1 flox mice,Animal Model,,,,,,Nf1 flox mice
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.95,animal_model,Nf1 fcr mice,Animal Model,,,,,,Nf1 fcr mice
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,animal_model,C57BL/6J mice,Animal Model,,,,,,C57BL/6J mice
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,computational_tool,Prism 4.0,Computational Tool,,,,,,Prism 4.0
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,cell_line,sNF96.2,Cell Line,,,,,,sNF96.2
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,cell_line,HEK293T,Cell Line,,,,,,HEK293T
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,cell_line,HT1080,Cell Line,,,,,,HT1080
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,genetic_reagent,Agilent Human miRNA Microarray V2,Genetic Reagent,,,,,,Agilent Human miRNA Microarray V2
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,computational_tool,Feature extractionTM software,Computational Tool,,,,,,Feature extractionTM software
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,computational_tool,limma package,Computational Tool,,,,,,limma package
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Filtlong v0.2.0,Computational Tool,,,,,,Filtlong v0.2.0
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Porechop v0.2.4,Computational Tool,,,,,,Porechop v0.2.4
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Flye v2.5,Computational Tool,,,,,,Flye v2.5
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,GCpp v1.0.0-1807624,Computational Tool,,,,,,GCpp v1.0.0-1807624
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,purge_haplotigs,Computational Tool,,,,,,purge_haplotigs
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Juicer v1.6.2,Computational Tool,,,,,,Juicer v1.6.2
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,3D-DNA v180114,Computational Tool,,,,,,3D-DNA v180114
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,BUSCO v5.7.0,Computational Tool,,,,,,BUSCO v5.7.0
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,QUASTv5.0.2,Computational Tool,,,,,,QUASTv5.0.2
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Liftoff v1.6.3,Computational Tool,,,,,,Liftoff v1.6.3
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,SnapGeneTM Version 7.2.1,Computational Tool,,,,,,SnapGeneTM Version 7.2.1
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,AlphaFold 3,Computational Tool,,,,,,AlphaFold 3
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,PyMOL Version 3.0.5,Computational Tool,,,,,,PyMOL Version 3.0.5
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Skewer v0.2.2.b,Computational Tool,,,,,,Skewer v0.2.2.b
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Tassel pipeline version 2,Computational Tool,,,,,,Tassel pipeline version 2
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,VCFtools v.0.1.16,Computational Tool,,,,,,VCFtools v.0.1.16
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Beagle v4.1,Computational Tool,,,,,,Beagle v4.1
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,itol v6.9.1,Computational Tool,,,,,,itol v6.9.1
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,Smart-seq2,Computational Tool,,,,,,Smart-seq2
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,scdDblFinder,Computational Tool,,,,,,scdDblFinder
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,scran,Computational Tool,,,,,,scran
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,QuPath,Computational Tool,,,,,,QuPath
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,computational_tool,GENIE (Genomics Evidence Neoplasia Information Exchange),Computational Tool,,,,,,GENIE (Genomics Evidence Neoplasia Information Exchange)
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,computational_tool,cBioPortal,Computational Tool,,,,,,cBioPortal
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,computational_tool,TCGA (The Cancer Genome Atlas),Computational Tool,,,,,,TCGA (The Cancer Genome Atlas)
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.95,cell_line,HEI-193,Cell Line,,,,,,HEI-193
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,cell_line,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",Cell Line,,,,,,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)"
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,cell_line,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",Cell Line,,,,,,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)"
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,cell_line,HEK-293T,Cell Line,,,,,,HEK-293T
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,minfi,Computational Tool,,,,,,minfi
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Seurat,Computational Tool,,,,,,Seurat
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Cell Ranger,Computational Tool,,,,,,Cell Ranger
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Signac,Computational Tool,,,,,,Signac
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,caret,Computational Tool,,,,,,caret
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,clinical_assessment_tool,Life Events Checklist (LEC),Clinical Assessment Tool,,,,,,Life Events Checklist (LEC)
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,clinical_assessment_tool,PROMIS depression short form,Clinical Assessment Tool,,,,,,PROMIS depression short form
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,clinical_assessment_tool,PROMIS pain interference short form,Clinical Assessment Tool,,,,,,PROMIS pain interference short form
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,clinical_assessment_tool,PROMIS cognitive function short form,Clinical Assessment Tool,,,,,,PROMIS cognitive function short form
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,clinical_assessment_tool,MEMS Cap,Clinical Assessment Tool,,,,,,MEMS Cap
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.8,clinical_assessment_tool,Barriers to Adherence Questionnaire,Clinical Assessment Tool,,,,,,Barriers to Adherence Questionnaire
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,computational_tool,Aardex MEMS Adherence Software (ElectronReader 0.9.9),Computational Tool,,,,,,Aardex MEMS Adherence Software (ElectronReader 0.9.9)
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,NanoDrop 2000,Computational Tool,,,,,,NanoDrop 2000
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.95,computational_tool,Ion Torrent Personal Genome Machine—Ion Torrent PGM™,Computational Tool,,,,,,Ion Torrent Personal Genome Machine—Ion Torrent PGM™
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Torrent Suite software,Computational Tool,,,,,,Torrent Suite software
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Ingenuity Variant Analysis software,Computational Tool,,,,,,Ingenuity Variant Analysis software
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Integrative Genomics Viewer,Computational Tool,,,,,,Integrative Genomics Viewer
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Alamut Visual,Computational Tool,,,,,,Alamut Visual
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,PolyPhen2,Computational Tool,,,,,,PolyPhen2
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,SIFT,Computational Tool,,,,,,SIFT
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,Human Splicing Finder,Computational Tool,,,,,,Human Splicing Finder
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,AB3130 Genetic Analyzer,Computational Tool,,,,,,AB3130 Genetic Analyzer
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,Sequencing Analysis software,Computational Tool,,,,,,Sequencing Analysis software
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,NF37,Cell Line,,,,,,NF37
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,NF87,Cell Line,,,,,,NF87
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,CT10,Cell Line,,,,,,CT10
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,CT11,Cell Line,,,,,,CT11
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,CT12,Cell Line,,,,,,CT12
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,computational_tool,FlowJo 7.6.5,Computational Tool,,,,,,FlowJo 7.6.5
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,computational_tool,"ImageJ software v.1.49 (NIH, USA)",Computational Tool,,,,,,"ImageJ software v.1.49 (NIH, USA)"
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,computational_tool,SPSS v. 20.0,Computational Tool,,,,,,SPSS v. 20.0
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,cell_line,CTL BJFF.6 hiPSCs,Cell Line,,,,,,CTL BJFF.6 hiPSCs
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,computational_tool,Karyostudio 1.3 software,Computational Tool,,,,,,Karyostudio 1.3 software
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,computational_tool,Partek Flow software,Computational Tool,,,,,,Partek Flow software
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,computational_tool,Imaris software,Computational Tool,,,,,,Imaris software
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.95,advanced_cellular_model,hiMGL cells,Advanced Cellular Model,,,,,,hiMGL cells
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,computational_tool,ChAMP,Computational Tool,,,,,,ChAMP
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,glmmTMB,Computational Tool,,,,,,glmmTMB
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,DMRcate,Computational Tool,,,,,,DMRcate
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,compartmap,Computational Tool,,,,,,compartmap
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,missMethyl,Computational Tool,,,,,,missMethyl
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,PAMES,Computational Tool,,,,,,PAMES
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,SeSAMe,Computational Tool,,,,,,SeSAMe
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,betareg,Computational Tool,,,,,,betareg
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,emmeans,Computational Tool,,,,,,emmeans
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,Dhh-Cre mice,Animal Model,,,,,,Dhh-Cre mice
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.95,cell_line,SNF02.2,Cell Line,,,,,,SNF02.2
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.95,cell_line,SNF96.2,Cell Line,,,,,,SNF96.2
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,computational_tool,MACS version 1.4.2,Computational Tool,,,,,,MACS version 1.4.2
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.95,clinical_assessment_tool,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,Clinical Assessment Tool,,,,,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.9,clinical_assessment_tool,EuroQol (EQ 5D),Clinical Assessment Tool,,,,,,EuroQol (EQ 5D)
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.85,clinical_assessment_tool,Riccardi NF severity grade classification,Clinical Assessment Tool,,,,,,Riccardi NF severity grade classification
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.8,clinical_assessment_tool,NIH Consensus Development Conference 1987 diagnostic criteria,Clinical Assessment Tool,,,,,,NIH Consensus Development Conference 1987 diagnostic criteria
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.85,clinical_assessment_tool,Impact of Pediatric Illness Scale,Clinical Assessment Tool,,,,,,Impact of Pediatric Illness Scale
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,clinical_assessment_tool,Pain Management Inventory,Clinical Assessment Tool,,,,,,Pain Management Inventory
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,clinical_assessment_tool,Post-Treatment Questionnaire,Clinical Assessment Tool,,,,,,Post-Treatment Questionnaire
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,computational_tool,3D Slicer,Computational Tool,,,,,,3D Slicer
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,clinical_assessment_tool,visual analogue scale,Clinical Assessment Tool,,,,,,visual analogue scale
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,animal_model,Nf1flox/flox mice,Animal Model,,,,,,Nf1flox/flox mice
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,cell_line,human endothelial colony forming cells (ECFC),Cell Line,,,,,,human endothelial colony forming cells (ECFC)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,cell_line,human microvascular endothelial cells (HMVEC),Cell Line,,,,,,human microvascular endothelial cells (HMVEC)
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,cell_line,293FT packaging cells,Cell Line,,,,,,293FT packaging cells
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,computational_tool,GraphPad Prism version 6.0h,Computational Tool,,,,,,GraphPad Prism version 6.0h
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.85,antibody,S100 B,Antibody,,,,,,S100 B
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,computational_tool,SPSS 25,Computational Tool,,,,,,SPSS 25
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,clinical_assessment_tool,NeuroConn DC-STIMULATOR MR,Clinical Assessment Tool,,,,,,NeuroConn DC-STIMULATOR MR
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,SimNIBS 3.2,Computational Tool,,,,,,SimNIBS 3.2
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,SPM8,Computational Tool,,,,,,SPM8
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,jMRUI5.1,Computational Tool,,,,,,jMRUI5.1
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,SPM12,Computational Tool,,,,,,SPM12
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,clinical_assessment_tool,Vineland Adaptive Behaviour Scale—third edition,Clinical Assessment Tool,,,,,,Vineland Adaptive Behaviour Scale—third edition
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,clinical_assessment_tool,Conners 3 rating scale,Clinical Assessment Tool,,,,,,Conners 3 rating scale
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,Psychopy2,Computational Tool,,,,,,Psychopy2
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,SPSS version25,Computational Tool,,,,,,SPSS version25
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,R version 1.2,Computational Tool,,,,,,R version 1.2
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,MATLAB R2014a,Computational Tool,,,,,,MATLAB R2014a
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,animal_model,Nf1 ± mice,Animal Model,,,,,,Nf1 ± mice
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,animal_model,Nf1 flox/flox,Animal Model,,,,,,Nf1 flox/flox
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,animal_model,hGFAP-Cre,Animal Model,,,,,,hGFAP-Cre
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,computational_tool,Imaris × 64 version 9.6–9.9,Computational Tool,,,,,,Imaris × 64 version 9.6–9.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,computational_tool,IGOR Pro 6.37,Computational Tool,,,,,,IGOR Pro 6.37
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,computational_tool,MaxQuant version 1.6.10.43,Computational Tool,,,,,,MaxQuant version 1.6.10.43
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,computational_tool,Prism 7,Computational Tool,,,,,,Prism 7
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,computational_tool,wANNOVAR web server,Computational Tool,,,,,,wANNOVAR web server
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,computational_tool,SeqMule,Computational Tool,,,,,,SeqMule
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,Codon Code Aligner,Computational Tool,,,,,,Codon Code Aligner
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,computational_tool,primer 3 (v. 0.4.0),Computational Tool,,,,,,primer 3 (v. 0.4.0)
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Wechsler Adult and Children Intelligence Scales,Clinical Assessment Tool,,,,,,Wechsler Adult and Children Intelligence Scales
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,Corsi block-tapping task,Clinical Assessment Tool,,,,,,Corsi block-tapping task
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),Clinical Assessment Tool,,,,,,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III)
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,School Achievement Test,Clinical Assessment Tool,,,,,,School Achievement Test
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,clinical_assessment_tool,Brazilian Criterion for Economic Classification (CCEB),Clinical Assessment Tool,,,,,,Brazilian Criterion for Economic Classification (CCEB)
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,computational_tool,Stratagene Mx3005 – MxPro QPCR-Software,Computational Tool,,,,,,Stratagene Mx3005 – MxPro QPCR-Software
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.75,computational_tool,SPSS 20.0,Computational Tool,,,,,,SPSS 20.0
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,TM-31,Cell Line,,,,,,TM-31
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,cell_line,LN319,Cell Line,,,,,,LN319
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,17,Cell Line,,,,,,17
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,5653,Cell Line,,,,,,5653
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,5746,Cell Line,,,,,,5746
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,computational_tool,Incucyte S3 Live-Cell Analysis System,Computational Tool,,,,,,Incucyte S3 Live-Cell Analysis System
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,computational_tool,synergyfinder,Computational Tool,,,,,,synergyfinder
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,advanced_cellular_model,spheroid culture system,Advanced Cellular Model,,,,,,spheroid culture system
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,cell_line,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",Cell Line,,,,,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)"
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,computational_tool,"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",Computational Tool,,,,,,"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)"
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,cell_line,MPNST,Cell Line,,,,,,MPNST
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,cell_line,ST8814,Cell Line,,,,,,ST8814
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,cell_line,LS141,Cell Line,,,,,,LS141
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,cell_line,DDLS,Cell Line,,,,,,DDLS
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,computational_tool,FlowJo software,Computational Tool,,,,,,FlowJo software
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.8,computational_tool,Python version 3.10,Computational Tool,,,,,,Python version 3.10
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.75,clinical_assessment_tool,Ki-67/MIB-1 index,Clinical Assessment Tool,,,,,,Ki-67/MIB-1 index
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,cell_line,Human Schwann cells (HSCs),Cell Line,,,,,,Human Schwann cells (HSCs)
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,cell_line,RT4-D6P2T schwannoma cells,Cell Line,,,,,,RT4-D6P2T schwannoma cells
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,cell_line,HEI-193,Cell Line,,,,,,HEI-193
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,computational_tool,SPSS 17.0,Computational Tool,,,,,,SPSS 17.0
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,computational_tool,Imaris software,Computational Tool,,,,,,Imaris software
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,clinical_assessment_tool,Rey complex figure test,Clinical Assessment Tool,,,,,,Rey complex figure test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,clinical_assessment_tool,cancellation test,Clinical Assessment Tool,,,,,,cancellation test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,clinical_assessment_tool,prism adaptation task,Clinical Assessment Tool,,,,,,prism adaptation task
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,clinical_assessment_tool,Stroop color word test,Clinical Assessment Tool,,,,,,Stroop color word test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.95,clinical_assessment_tool,Wechsler Intelligence Scale for Children–Revised,Clinical Assessment Tool,,,,,,Wechsler Intelligence Scale for Children–Revised
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,clinical_assessment_tool,Beery developmental test of visual-motor integration,Clinical Assessment Tool,,,,,,Beery developmental test of visual-motor integration
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,clinical_assessment_tool,judgment of line orientation task,Clinical Assessment Tool,,,,,,judgment of line orientation task
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,computational_tool,SPSS 12.0,Computational Tool,,,,,,SPSS 12.0
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,animal_model,Nf1 mice,Animal Model,,,,,,Nf1 mice
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,cell_line,HEK 293T cell line,Cell Line,,,,,,HEK 293T cell line
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,cell_line,LN428 human glioblastoma multiforme (GBM) cell line,Cell Line,,,,,,LN428 human glioblastoma multiforme (GBM) cell line
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.95,animal_model,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",Animal Model,,,,,,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO"
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,computational_tool,Mutalyzer 2.0,Computational Tool,,,,,,Mutalyzer 2.0
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,computational_tool,FusionCharts v3,Computational Tool,,,,,,FusionCharts v3
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,cell_line,C2C12,Cell Line,,,,,,C2C12
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.9,computational_tool,DESeq2 (version 1.12.4),Computational Tool,,,,,,DESeq2 (version 1.12.4)
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.8,computational_tool,PRISM (version 8),Computational Tool,,,,,,PRISM (version 8)
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,cell_line,ipNF95.11b C,Cell Line,,,,,,ipNF95.11b C
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,cell_line,ipNF05.5,Cell Line,,,,,,ipNF05.5
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,advanced_cellular_model,TAME chips,Advanced Cellular Model,,,,,,TAME chips
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,computational_tool,Volocity software (Version 7.0.0),Computational Tool,,,,,,Volocity software (Version 7.0.0)
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,computational_tool,ImageJ 1.54g software,Computational Tool,,,,,,ImageJ 1.54g software
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,computational_tool,Insight Toolkit,Computational Tool,,,,,,Insight Toolkit
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,computational_tool,Slicer,Computational Tool,,,,,,Slicer
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.9,cell_line,BL21(DE3) Star,Cell Line,,,,,,BL21(DE3) Star
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,iHSC1λ,Cell Line,,,,,,iHSC1λ
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,iHSC2λ,Cell Line,,,,,,iHSC2λ
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,S462-TY,Cell Line,,,,,,S462-TY
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,ST8814,Cell Line,,,,,,ST8814
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,STS-26T,Cell Line,,,,,,STS-26T
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,computational_tool,CalcuSyn Version 2.1,Computational Tool,,,,,,CalcuSyn Version 2.1
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,cell_line,NF1-null 293T cells,Cell Line,,,,,,NF1-null 293T cells
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,cell_line,ipNF95.11b C,Cell Line,,,,,,ipNF95.11b C
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,genetic_reagent,psPAX2,Genetic Reagent,,,,,,psPAX2
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,genetic_reagent,pMD2.G,Genetic Reagent,,,,,,pMD2.G
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,computational_tool,RELION,Computational Tool,,,,,,RELION
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,computational_tool,bwa-mem v0.7.10,Computational Tool,,,,,,bwa-mem v0.7.10
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,computational_tool,"GATK, version 1.0.4705",Computational Tool,,,,,,"GATK, version 1.0.4705"
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,computational_tool,VisCap,Computational Tool,,,,,,VisCap
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,clinical_assessment_tool,Cirrus HD-OCT,Clinical Assessment Tool,,,,,,Cirrus HD-OCT
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,Teller acuity cards,Clinical Assessment Tool,,,,,,Teller acuity cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,Cardiff acuity cards,Clinical Assessment Tool,,,,,,Cardiff acuity cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,Lea cards,Clinical Assessment Tool,,,,,,Lea cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,KM (Konstantin Moutakis) cards,Clinical Assessment Tool,,,,,,KM (Konstantin Moutakis) cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,clinical_assessment_tool,Humphrey Field Analyzer perimetry,Clinical Assessment Tool,,,,,,Humphrey Field Analyzer perimetry
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,clinical_assessment_tool,World Health Organization Categories of Childhood VI scale,Clinical Assessment Tool,,,,,,World Health Organization Categories of Childhood VI scale
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,cell_line,Primary human Schwann cells (NHSC),Cell Line,,,,,,Primary human Schwann cells (NHSC)
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,cell_line,Mouse embryonic fibroblasts (MEFs),Cell Line,,,,,,Mouse embryonic fibroblasts (MEFs)
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Numerical Rating Scale (NRS-11),Clinical Assessment Tool,,,,,,Numerical Rating Scale (NRS-11)
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Pain Interference Index,Clinical Assessment Tool,,,,,,Pain Interference Index
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,Clinical Assessment Tool,,,,,,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Global Impression of Change scale,Clinical Assessment Tool,,,,,,Global Impression of Change scale
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,Clinical Assessment Tool,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,Clinical Assessment Tool,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,"NCI Common Terminology Criteria for Adverse Events, version 4.0",Clinical Assessment Tool,,,,,,"NCI Common Terminology Criteria for Adverse Events, version 4.0"
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-002,Cell Line,,,,,,JH-2-002
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-031,Cell Line,,,,,,JH-2-031
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-079c,Cell Line,,,,,,JH-2-079c
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-103,Cell Line,,,,,,JH-2-103
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,JH-2-002 PDX,Patient-Derived Model,,,,,,JH-2-002 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,JH-2-031 PDX,Patient-Derived Model,,,,,,JH-2-031 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,JH-2-079c PDX,Patient-Derived Model,,,,,,JH-2-079c PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,WU-225 PDX,Patient-Derived Model,,,,,,WU-225 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,WU-386 PDX,Patient-Derived Model,,,,,,WU-386 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,WU-545 PDX,Patient-Derived Model,,,,,,WU-545 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,MN-2 PDX,Patient-Derived Model,,,,,,MN-2 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,MN-3-002 PDX,Patient-Derived Model,,,,,,MN-3-002 PDX
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Trimmomatic v0.39,Computational Tool,,,,,,Trimmomatic v0.39
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,BWA-MEM,Computational Tool,,,,,,BWA-MEM
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,GATK V4.2,Computational Tool,,,,,,GATK V4.2
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Pindel,Computational Tool,,,,,,Pindel
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,FlowJo 10.8,Computational Tool,,,,,,FlowJo 10.8
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,animal_model,Nf1 P1,Animal Model,,,,,,Nf1 P1
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,PCB-Gal4,Genetic Reagent,,,,,,PCB-Gal4
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,PhenoCapture 3.3,Computational Tool,,,,,,PhenoCapture 3.3
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,Fiji 2.0,Computational Tool,,,,,,Fiji 2.0
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,T2/Onc15,Genetic Reagent,,,,,,T2/Onc15
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,iHSCs,Cell Line,,,,,,iHSCs
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,S462-TY,Cell Line,,,,,,S462-TY
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,cell_line,K562,Cell Line,,,,,,K562
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,computational_tool,GeneSpring GX v7.3.1,Computational Tool,,,,,,GeneSpring GX v7.3.1
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,cell_line,icNF 97.2a,Cell Line,,,,,,icNF 97.2a
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,cell_line,icNF 97.2b,Cell Line,,,,,,icNF 97.2b
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,cell_line,icNF 98.4d,Cell Line,,,,,,icNF 98.4d
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,Cell Ranger pipeline v7.1.0,Computational Tool,,,,,,Cell Ranger pipeline v7.1.0
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,Seurat v4.3.0–v5,Computational Tool,,,,,,Seurat v4.3.0–v5
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,Ingenuity Pathway Analysis (IPA),Computational Tool,,,,,,Ingenuity Pathway Analysis (IPA)
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,scanpy,Computational Tool,,,,,,scanpy
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,CellChat,Computational Tool,,,,,,CellChat
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,genetic_reagent,"Klenow (exo-)(cat# E6053, NEB)",Genetic Reagent,,,,,,"Klenow (exo-)(cat# E6053, NEB)"
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,computational_tool,Illumina CASAVA software (v1.8),Computational Tool,,,,,,Illumina CASAVA software (v1.8)
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,computational_tool,RealSeqS,Computational Tool,,,,,,RealSeqS
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,cell_line,293T cells,Cell Line,,,,,,293T cells
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.95,cell_line,sNF96.2,Cell Line,,,,,,sNF96.2
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,cell_line,HFFs,Cell Line,,,,,,HFFs
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,cell_line,NCI-H266,Cell Line,,,,,,NCI-H266
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,cell_line,K562,Cell Line,,,,,,K562
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,genetic_reagent,anti-HER1 CAR (806),Genetic Reagent,,,,,,anti-HER1 CAR (806)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,genetic_reagent,anti-HER1 CAR (E2),Genetic Reagent,,,,,,anti-HER1 CAR (E2)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,genetic_reagent,anti-HER1 CAR (NEC),Genetic Reagent,,,,,,anti-HER1 CAR (NEC)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,BWA version 0.7.15,Computational Tool,,,,,,BWA version 0.7.15
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,GATK MuTect2 (version 4.1),Computational Tool,,,,,,GATK MuTect2 (version 4.1)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,ANNOVAR (version 2016-02-01),Computational Tool,,,,,,ANNOVAR (version 2016-02-01)
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,advanced_cellular_model,3D tumor spheroid model,Advanced Cellular Model,,,,,,3D tumor spheroid model
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,cell_line,Neurofibromatosis 1 fibroblasts,Cell Line,,,,,,Neurofibromatosis 1 fibroblasts
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.95,animal_model,Postn-Cre; Nf2flox/flox,Animal Model,,,,,,Postn-Cre; Nf2flox/flox
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,animal_model,Nf2flox/flox,Animal Model,,,,,,Nf2flox/flox
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,computational_tool,SAS 9.4,Computational Tool,,,,,,SAS 9.4
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,computational_tool,ParaVision 6.0.1,Computational Tool,,,,,,ParaVision 6.0.1
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,cell_line,iHSCs,Cell Line,,,,,,iHSCs
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,cell_line,S462-TY,Cell Line,,,,,,S462-TY
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,animal_model,"Dhh::Cre, Nf1fl/fl, Pten",Animal Model,,,,,,"Dhh::Cre, Nf1fl/fl, Pten"
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,Trimmomatic (v0.33),Computational Tool,,,,,,Trimmomatic (v0.33)
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,HISAT2 (v2.1.0),Computational Tool,,,,,,HISAT2 (v2.1.0)
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,StringTie (v1.3.4d),Computational Tool,,,,,,StringTie (v1.3.4d)
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,DESeq2 (v1.42.0),Computational Tool,,,,,,DESeq2 (v1.42.0)
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.8,computational_tool,GeneAnalytics(v),Computational Tool,,,,,,GeneAnalytics(v)
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,patient_derived_model,Patient-derived xenograft (PDX) MPNST model,Patient-Derived Model,,,,,,Patient-derived xenograft (PDX) MPNST model
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,animal_model,Mut3,Animal Model,,,,,,Mut3
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,animal_model,Mut4,Animal Model,,,,,,Mut4
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,advanced_cellular_model,neurosphere cultures,Advanced Cellular Model,,,,,,neurosphere cultures
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,animal_model,Nf1^flox/flox;GFAP-Cre mice,Animal Model,,,,,,Nf1^flox/flox;GFAP-Cre mice
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,computational_tool,Bruker AutoFlex III mass spectrometer,Computational Tool,,,,,,Bruker AutoFlex III mass spectrometer
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,computational_tool,FlexImaging 4.0,Computational Tool,,,,,,FlexImaging 4.0
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,computational_tool,Thermo LTQ Velos Orbitrap mass spectrometer,Computational Tool,,,,,,Thermo LTQ Velos Orbitrap mass spectrometer
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,TagIdent,Computational Tool,,,,,,TagIdent
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,protein prospector MS-product,Computational Tool,,,,,,protein prospector MS-product
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,computational_tool,GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,Computational Tool,,,,,,GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,computational_tool,SPSS 20.0,Computational Tool,,,,,,SPSS 20.0
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.9,computational_tool,Bioconductor limma package,Computational Tool,,,,,,Bioconductor limma package
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.75,genetic_reagent,Human Universal Reference RNA,Genetic Reagent,,,,,,Human Universal Reference RNA
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,MPNST-SP-01,Cell Line,,,,,,MPNST-SP-01
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,MPNST-NF1-08,Cell Line,,,,,,MPNST-NF1-08
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,MPNST-NF1-9,Cell Line,,,,,,MPNST-NF1-9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,STS-26T,Cell Line,,,,,,STS-26T
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,HS-PSS,Cell Line,,,,,,HS-PSS
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,HS-sch2,Cell Line,,,,,,HS-sch2
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,S462,Cell Line,,,,,,S462
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,sNF96.2,Cell Line,,,,,,sNF96.2
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,cell_line,Human Foreskin Fibroblast (HFF),Cell Line,,,,,,Human Foreskin Fibroblast (HFF)
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,MPNST-SP-01 PDOX,Patient-Derived Model,,,,,,MPNST-SP-01 PDOX
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,MPNST-NF1-09 PDOX,Patient-Derived Model,,,,,,MPNST-NF1-09 PDOX
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,computational_tool,GraphPad Prism Version 6,Computational Tool,,,,,,GraphPad Prism Version 6
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.95,animal_model,DhhCre;Nf1fl/fl,Animal Model,,,,,,DhhCre;Nf1fl/fl
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,clinical_assessment_tool,volumetric magnetic resonance imaging analysis,Clinical Assessment Tool,,,,,,volumetric magnetic resonance imaging analysis
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.8,clinical_assessment_tool,Responsibility for Medication Questionnaire,Clinical Assessment Tool,,,,,,Responsibility for Medication Questionnaire
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",Clinical Assessment Tool,,,,,,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0"
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,clinical_assessment_tool,Response Evaluation Criteria In Solid Tumors (RECIST),Clinical Assessment Tool,,,,,,Response Evaluation Criteria In Solid Tumors (RECIST)
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,clinical_assessment_tool,World Health Organization (WHO) criteria,Clinical Assessment Tool,,,,,,World Health Organization (WHO) criteria
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,cell_line,ipNF95.11b C,Cell Line,,,,,,ipNF95.11b C
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,cell_line,ipNF95.11b C-RFP,Cell Line,,,,,,ipNF95.11b C-RFP
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,cell_line,ipNF 05.5,Cell Line,,,,,,ipNF 05.5
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.85,advanced_cellular_model,3D rBM overlay model,Advanced Cellular Model,,,,,,3D rBM overlay model
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,computational_tool,Volocity software 7.0.0,Computational Tool,,,,,,Volocity software 7.0.0
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,computational_tool,Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,Computational Tool,,,,,,Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,,ImageJ software
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,computational_tool,GraphPad Prism version 8.0.1,Computational Tool,,,,,,GraphPad Prism version 8.0.1
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,computational_tool,Image J software,Computational Tool,,,,,,Image J software
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,patient_derived_model,vestibular schwannoma xenografts,Patient-Derived Model,,,,,,vestibular schwannoma xenografts
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,computational_tool,Simpleware,Computational Tool,,,,,,Simpleware
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,cell_line,Ben-Men-1,Cell Line,,,,,,Ben-Men-1
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,cell_line,AC007-hTERT,Cell Line,,,,,,AC007-hTERT
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,cell_line,AC028,Cell Line,,,,,,AC028
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,cell_line,293T,Cell Line,,,,,,293T
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,computational_tool,GraphPad Prism 6.0,Computational Tool,,,,,,GraphPad Prism 6.0
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,computational_tool,Oligo 5.0 computer program,Computational Tool,,,,,,Oligo 5.0 computer program
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.85,clinical_assessment_tool,Likert scale questionnaire,Clinical Assessment Tool,,,,,,Likert scale questionnaire
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.85,clinical_assessment_tool,CNC-word test,Clinical Assessment Tool,,,,,,CNC-word test
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,LIFE-R Questionnaire,Clinical Assessment Tool,,,,,,LIFE-R Questionnaire
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Rex Gauge durometer,Clinical Assessment Tool,,,,,,Rex Gauge durometer
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Delfin SkinFibroMeter,Clinical Assessment Tool,,,,,,Delfin SkinFibroMeter
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.8,computational_tool,R 4.4.2 software,Computational Tool,,,,,,R 4.4.2 software
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,cell_line,U87-MG,Cell Line,,,,,,U87-MG
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,cell_line,HEK293T,Cell Line,,,,,,HEK293T
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,Sci-kit Learn,Computational Tool,,,,,,Sci-kit Learn
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,computational_tool,python 3.5.1,Computational Tool,,,,,,python 3.5.1
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,Li-COR Image Studio Lite 5.0,Computational Tool,,,,,,Li-COR Image Studio Lite 5.0
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,computational_tool,R version 3.2.3,Computational Tool,,,,,,R version 3.2.3
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,WGCNA,Computational Tool,,,,,,WGCNA
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,computational_tool,nf1_inactivation GitHub repository,Computational Tool,,,,,,nf1_inactivation GitHub repository
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,GeneChip Human Transcriptome Array 2.0,Computational Tool,,,,,,GeneChip Human Transcriptome Array 2.0
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.9,cell_line,Meso-33,Cell Line,,,,,,Meso-33
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.9,cell_line,FC-1801,Cell Line,,,,,,FC-1801
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.85,cell_line,293T,Cell Line,,,,,,293T
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.75,genetic_reagent,Ultra Low Cluster Plates,Genetic Reagent,,,,,,Ultra Low Cluster Plates
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,cell_line,NIH-3T3,Cell Line,,,,,,NIH-3T3
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.85,cell_line,φNX packaging cell line,Cell Line,,,,,,φNX packaging cell line
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,genetic_reagent,GST-PID,Genetic Reagent,,,,,,GST-PID
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,genetic_reagent,Gst-PID L107F,Genetic Reagent,,,,,,Gst-PID L107F
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,H1838,Cell Line,,,,,,H1838
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,WM3918,Cell Line,,,,,,WM3918
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,M308,Cell Line,,,,,,M308
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,ST8814,Cell Line,,,,,,ST8814
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF90.8,Cell Line,,,,,,NF90.8
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF94.3,Cell Line,,,,,,NF94.3
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF96.2,Cell Line,,,,,,NF96.2
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF10.1,Cell Line,,,,,,NF10.1
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF11.1,Cell Line,,,,,,NF11.1
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–002,Patient-Derived Model,,,,,,JH-2–002
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–009,Patient-Derived Model,,,,,,JH-2–009
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–031,Patient-Derived Model,,,,,,JH-2–031
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–055,Patient-Derived Model,,,,,,JH-2–055
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–060,Patient-Derived Model,,,,,,JH-2–060
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–074,Patient-Derived Model,,,,,,JH-2–074
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–077,Patient-Derived Model,,,,,,JH-2–077
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,computational_tool,BioNavigator software V.6.3,Computational Tool,,,,,,BioNavigator software V.6.3
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,PDX JH-2–002,Patient-Derived Model,,,,,,PDX JH-2–002
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Vectra H1,Clinical Assessment Tool,,,,,,Vectra H1
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,LifeViz Micro,Clinical Assessment Tool,,,,,,LifeViz Micro
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Cherry Imaging,Clinical Assessment Tool,,,,,,Cherry Imaging
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.8,computational_tool,IBM SPSS Statistics,Computational Tool,,,,,,IBM SPSS Statistics
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.95,computational_tool,PERADIGM,Computational Tool,,,,,,PERADIGM
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,computational_tool,PLINK,Computational Tool,,,,,,PLINK
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,computational_tool,Word2Vec,Computational Tool,,,,,,Word2Vec
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.95,animal_model,Nf1Prx1,Animal Model,,,,,,Nf1Prx1
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.95,animal_model,Nf1Col1,Animal Model,,,,,,Nf1Col1
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,antibody,panendothelial cell antigen,Antibody,,,,,,panendothelial cell antigen
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,computational_tool,skyscan 1172,Computational Tool,,,,,,skyscan 1172
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,computational_tool,Labview 7.0,Computational Tool,,,,,,Labview 7.0
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,genetic_reagent,I2HCP panel,Genetic Reagent,,,,,,I2HCP panel
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,BWA mem,Computational Tool,,,,,,BWA mem
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,bam-readcount,Computational Tool,,,,,,bam-readcount
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,regioneR,Computational Tool,,,,,,regioneR
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,CLC Genomics Workbench v6,Computational Tool,,,,,,CLC Genomics Workbench v6
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,animal_model,Nf1(fl/fl);DhhCre,Animal Model,,,,,,Nf1(fl/fl);DhhCre
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,animal_model,Stat3(fl/fl);Nf1(fl/fl);DhhCre,Animal Model,,,,,,Stat3(fl/fl);Nf1(fl/fl);DhhCre
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,Ki67,Antibody,,,,,,Ki67
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,genetic_reagent,shRNAs,Genetic Reagent,,,,,,shRNAs
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,advanced_cellular_model,neurofibroma spheres,Advanced Cellular Model,,,,,,neurofibroma spheres
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,advanced_cellular_model,embryonic mouse spheres,Advanced Cellular Model,,,,,,embryonic mouse spheres
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S193,Genetic Reagent,,,,,,D22S193
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,NF2 TET,Genetic Reagent,,,,,,NF2 TET
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S929,Genetic Reagent,,,,,,D22S929
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S268,Genetic Reagent,,,,,,D22S268
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S430,Genetic Reagent,,,,,,D22S430
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,genetic_reagent,BstUI,Genetic Reagent,,,,,,BstUI
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,animal_model,Nf1f/f;Trp53f/f;Nes-TK,Animal Model,,,,,,Nf1f/f;Trp53f/f;Nes-TK
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,animal_model,Nf1f/f;Trp53f/f;CGD,Animal Model,,,,,,Nf1f/f;Trp53f/f;CGD
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.85,animal_model,cisNP,Animal Model,,,,,,cisNP
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,Seurat V3.0,Computational Tool,,,,,,Seurat V3.0
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,STAR 2.4.2.8,Computational Tool,,,,,,STAR 2.4.2.8
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,GSVA package,Computational Tool,,,,,,GSVA package
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,Limma package,Computational Tool,,,,,,Limma package
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Nf1-/- mice,Animal Model,,,,,,Nf1-/- mice
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Nf1fl mice,Animal Model,,,,,,Nf1fl mice
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,cell_line,BY4743 background diploid yeast deletion strains,Cell Line,,,,,,BY4743 background diploid yeast deletion strains
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,cell_line,Y258 background haploid yeast MORF strain,Cell Line,,,,,,Y258 background haploid yeast MORF strain
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,cell_line,MethoCult® M3434,Cell Line,,,,,,MethoCult® M3434
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,computational_tool,GraphPad Prism version 5.01,Computational Tool,,,,,,GraphPad Prism version 5.01
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,computational_tool,STATA 11,Computational Tool,,,,,,STATA 11
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,computational_tool,Schrödinger software suite release 2017–1,Computational Tool,,,,,,Schrödinger software suite release 2017–1
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,computational_tool,AMBER16,Computational Tool,,,,,,AMBER16
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,computational_tool,VMD (version 1.9.3),Computational Tool,,,,,,VMD (version 1.9.3)
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,computational_tool,gromacs (version 4.6),Computational Tool,,,,,,gromacs (version 4.6)
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,computational_tool,MATLAB version 2019b,Computational Tool,,,,,,MATLAB version 2019b
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,PredictSNP2,Computational Tool,,,,,,PredictSNP2
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,iStable,Computational Tool,,,,,,iStable
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,Align GVGD,Computational Tool,,,,,,Align GVGD
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,AlphaFold3,Computational Tool,,,,,,AlphaFold3
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,computational_tool,SNPeffect 4.0,Computational Tool,,,,,,SNPeffect 4.0
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,computational_tool,iMutant 2.0,Computational Tool,,,,,,iMutant 2.0
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.8,clinical_assessment_tool,nerve conduction velocity,Clinical Assessment Tool,,,,,,nerve conduction velocity
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.75,clinical_assessment_tool,electrophysiological measurements,Clinical Assessment Tool,,,,,,electrophysiological measurements
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.9,cell_line,K4622 grade II glioma cell line,Cell Line,,,,,,K4622 grade II glioma cell line
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,computational_tool,Gel-Pro Analyzer 4.0 software,Computational Tool,,,,,,Gel-Pro Analyzer 4.0 software
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,computational_tool,R statistical package,Computational Tool,,,,,,R statistical package
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Morris water maze,Clinical Assessment Tool,,,,,,Morris water maze
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Rotarod,Clinical Assessment Tool,,,,,,Rotarod
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.75,genetic_reagent,biocytin,Genetic Reagent,,,,,,biocytin
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,HSR-GBM1,Cell Line,,,,,,HSR-GBM1
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHH-520,Cell Line,,,,,,JHH-520
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHU-0879,Cell Line,,,,,,JHU-0879
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHU-1016B,Cell Line,,,,,,JHU-1016B
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHH-136,Cell Line,,,,,,JHH-136
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,B76,Cell Line,,,,,,B76
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,NGT-41,Cell Line,,,,,,NGT-41
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,NMCG-1,Cell Line,,,,,,NMCG-1
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,DBTRG,Cell Line,,,,,,DBTRG
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,cell_line,LN229,Cell Line,,,,,,LN229
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,cell_line,T98G,Cell Line,,,,,,T98G
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,computational_tool,SynergyFinder,Computational Tool,,,,,,SynergyFinder
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,computational_tool,Qupath,Computational Tool,,,,,,Qupath
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,cell_line,M059J,Cell Line,,,,,,M059J
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,U87,Cell Line,,,,,,U87
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,U118,Cell Line,,,,,,U118
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,U251,Cell Line,,,,,,U251
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,A172,Cell Line,,,,,,A172
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,computational_tool,SPSS version 19.0,Computational Tool,,,,,,SPSS version 19.0
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,clinical_assessment_tool,EGI 128-electrode Hydrocel Sensor Net,Clinical Assessment Tool,,,,,,EGI 128-electrode Hydrocel Sensor Net
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,clinical_assessment_tool,Mullen Scales of Early Learning (MSEL),Clinical Assessment Tool,,,,,,Mullen Scales of Early Learning (MSEL)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,clinical_assessment_tool,Autism Observation Score for Infants (AOSI),Clinical Assessment Tool,,,,,,Autism Observation Score for Infants (AOSI)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,clinical_assessment_tool,Infant Behaviour Questionnaire-Revised (IBQ-R),Clinical Assessment Tool,,,,,,Infant Behaviour Questionnaire-Revised (IBQ-R)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,clinical_assessment_tool,MacArthur Bates Communicative Development Inventory (CDI),Clinical Assessment Tool,,,,,,MacArthur Bates Communicative Development Inventory (CDI)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,clinical_assessment_tool,NIH consensus criteria,Clinical Assessment Tool,,,,,,NIH consensus criteria
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,U87,Cell Line,,,,,,U87
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,U251,Cell Line,,,,,,U251
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,MiaPaCa-2,Cell Line,,,,,,MiaPaCa-2
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,PANC1,Cell Line,,,,,,PANC1
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,BxPc3,Cell Line,,,,,,BxPc3
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.95,cell_line,ipNF95.6,Cell Line,,,,,,ipNF95.6
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,cell_line,HEK 293T,Cell Line,,,,,,HEK 293T
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,genetic_reagent,psPAX,Genetic Reagent,,,,,,psPAX
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,genetic_reagent,pMD2.G,Genetic Reagent,,,,,,pMD2.G
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,computational_tool,CHOPCHOP,Computational Tool,,,,,,CHOPCHOP
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,computational_tool,Ethovision 11,Computational Tool,,,,,,Ethovision 11
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,cell_line,PNF-derived Schwann cells,Cell Line,,,,,,PNF-derived Schwann cells
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,computational_tool,Vevo 2100 micro-imaging system,Computational Tool,,,,,,Vevo 2100 micro-imaging system
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,computational_tool,Vevo software version 5.0.0,Computational Tool,,,,,,Vevo software version 5.0.0
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,computational_tool,Chipster software,Computational Tool,,,,,,Chipster software
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,computational_tool,R bioconductor,Computational Tool,,,,,,R bioconductor
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,animal_model,Nf1flox/flox,Animal Model,,,,,,Nf1flox/flox
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,computational_tool,ARACNe-AP algorithm,Computational Tool,,,,,,ARACNe-AP algorithm
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,computational_tool,DESeq2 version 1.18.1,Computational Tool,,,,,,DESeq2 version 1.18.1
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,cell_line,Wild-type and Nf1-/- primary astrocytes,Cell Line,,,,,,Wild-type and Nf1-/- primary astrocytes
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,Dragen program,Computational Tool,,,,,,Dragen program
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,GATK pipeline,Computational Tool,,,,,,GATK pipeline
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,VarDict,Computational Tool,,,,,,VarDict
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,HumanOmni2.5-8,Genetic Reagent,,,,,,HumanOmni2.5-8
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,HudsonAlpha RNA-seq data analysis pipeline,Computational Tool,,,,,,HudsonAlpha RNA-seq data analysis pipeline
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,computational_tool,TopHat v2.0,Computational Tool,,,,,,TopHat v2.0
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,computational_tool,Cufflinks v0.9.3,Computational Tool,,,,,,Cufflinks v0.9.3
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,FeatureCounts,Computational Tool,,,,,,FeatureCounts
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.95,computational_tool,Cutaneous NF Github repository,Computational Tool,,,,,,Cutaneous NF Github repository
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,cell_line,JHH-520 cell line,Cell Line,,,,,,JHH-520 cell line
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,cell_line,GBM1 cell line,Cell Line,,,,,,GBM1 cell line
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,cell_line,JHH-0879 cell line,Cell Line,,,,,,JHH-0879 cell line
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,computational_tool,QuPath (v0.4.3),Computational Tool,,,,,,QuPath (v0.4.3)
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,computational_tool,R (version 4.3.1),Computational Tool,,,,,,R (version 4.3.1)
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,computational_tool,cBioportal,Computational Tool,,,,,,cBioportal
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,computational_tool,REDCap,Computational Tool,,,,,,REDCap
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,cell_line,Sf21 insect cells,Cell Line,,,,,,Sf21 insect cells
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,cell_line,E. coli DH10Multibac cells,Cell Line,,,,,,E. coli DH10Multibac cells
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,genetic_reagent,EndoPorter,Genetic Reagent,,,,,,EndoPorter
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,genetic_reagent,Lipofectamine RNAiMAX,Genetic Reagent,,,,,,Lipofectamine RNAiMAX
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,clinical_assessment_tool,"International Classification of Diseases, 10th Revision (ICD-10)",Clinical Assessment Tool,,,,,,"International Classification of Diseases, 10th Revision (ICD-10)"
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,clinical_assessment_tool,Systematized Nomenclature of Medicine (SNOMED),Clinical Assessment Tool,,,,,,Systematized Nomenclature of Medicine (SNOMED)
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,clinical_assessment_tool,Logical Observation Identifiers Names and Codes (LOINC),Clinical Assessment Tool,,,,,,Logical Observation Identifiers Names and Codes (LOINC)
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,clinical_assessment_tool,Nebraska Lexicon,Clinical Assessment Tool,,,,,,Nebraska Lexicon
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,computational_tool,R v3.6.3,Computational Tool,,,,,,R v3.6.3
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,BSDA v1.2.0,Computational Tool,,,,,,BSDA v1.2.0
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,gdata v2.18.0,Computational Tool,,,,,,gdata v2.18.0
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,ggplot2 v3.3.2,Computational Tool,,,,,,ggplot2 v3.3.2
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,,0.95,clinical_assessment_tool,NFTI-QOL,Clinical Assessment Tool,,,,,,NFTI-QOL
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.95,animal_model,Nf1fl/fl;DhhCre,Animal Model,,,,,,Nf1fl/fl;DhhCre
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,computational_tool,Affymetrix Mouse Gene 2.0 ST array,Computational Tool,,,,,,Affymetrix Mouse Gene 2.0 ST array
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,computational_tool,limma package,Computational Tool,,,,,,limma package
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,computational_tool,WebGestalt webserver,Computational Tool,,,,,,WebGestalt webserver
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,clinical_assessment_tool,"mouse cytokine array (panel A, R&D system)",Clinical Assessment Tool,,,,,,"mouse cytokine array (panel A, R&D system)"
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.85,computational_tool,MedCalc,Computational Tool,,,,,,MedCalc
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.85,clinical_assessment_tool,NIH Consensus Conference criteria,Clinical Assessment Tool,,,,,,NIH Consensus Conference criteria
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,clinical_assessment_tool,Lansky performance status,Clinical Assessment Tool,,,,,,Lansky performance status
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,clinical_assessment_tool,Karnofsky performance status,Clinical Assessment Tool,,,,,,Karnofsky performance status
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,clinical_assessment_tool,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,Clinical Assessment Tool,,,,,,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,clinical_assessment_tool,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),Clinical Assessment Tool,,,,,,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.8,computational_tool,Stata 15,Computational Tool,,,,,,Stata 15
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,xGen UDI-UMI Adapters,Genetic Reagent,,,,,,xGen UDI-UMI Adapters
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.9,computational_tool,ichorCNA,Computational Tool,,,,,,ichorCNA
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,TruSight Oncology 500,Genetic Reagent,,,,,,TruSight Oncology 500
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,computational_tool,Python sklearn,Computational Tool,,,,,,Python sklearn
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,computational_tool,ComplexHeatmap,Computational Tool,,,,,,ComplexHeatmap
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.95,animal_model,Nf1flox/flox,Animal Model,,,,,,Nf1flox/flox
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.95,animal_model,Nf1+/−,Animal Model,,,,,,Nf1+/−
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,computational_tool,Image J software,Computational Tool,,,,,,Image J software
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,computational_tool,10x Genomics Cell Ranger 7.0.1,Computational Tool,,,,,,10x Genomics Cell Ranger 7.0.1
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,computational_tool,Seurat V3 package,Computational Tool,,,,,,Seurat V3 package
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.95,clinical_assessment_tool,BoN (Burden of NF1) questionnaire,Clinical Assessment Tool,,,,,,BoN (Burden of NF1) questionnaire
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,clinical_assessment_tool,Dermatology Life Quality Index (DLQI),Clinical Assessment Tool,,,,,,Dermatology Life Quality Index (DLQI)
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,clinical_assessment_tool,SF12,Clinical Assessment Tool,,,,,,SF12
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.85,computational_tool,SAS software Version 9.4,Computational Tool,,,,,,SAS software Version 9.4
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,clinical_assessment_tool,Autism Diagnostic Interview Revised (ADI-R),Clinical Assessment Tool,,,,,,Autism Diagnostic Interview Revised (ADI-R)
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,clinical_assessment_tool,Autism Diagnostic Observation Schedule-2 (ADOS-2),Clinical Assessment Tool,,,,,,Autism Diagnostic Observation Schedule-2 (ADOS-2)
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,clinical_assessment_tool,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),Clinical Assessment Tool,,,,,,Wechsler Abbreviated Scale of Intelligence-II (WASI-II)
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,clinical_assessment_tool,"Conners Parent Rating Scale (3rd edition, short form)",Clinical Assessment Tool,,,,,,"Conners Parent Rating Scale (3rd edition, short form)"
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.85,computational_tool,SPSS version 25,Computational Tool,,,,,,SPSS version 25
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,clinical_assessment_tool,Magnetom Avanto,Clinical Assessment Tool,,,,,,Magnetom Avanto
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,computational_tool,Analyze 12.0,Computational Tool,,,,,,Analyze 12.0
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,computational_tool,MIM Encore 6.9.3,Computational Tool,,,,,,MIM Encore 6.9.3
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,S520,Cell Line,,,,,,S520
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,88-3,Cell Line,,,,,,88-3
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,90-8,Cell Line,,,,,,90-8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,YST1,Cell Line,,,,,,YST1
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,genetic_reagent,hTERT,Genetic Reagent,,,,,,hTERT
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,genetic_reagent,mCdk4,Genetic Reagent,,,,,,mCdk4
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF97.2a,Cell Line,,,,,,icNF97.2a
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF97.2b,Cell Line,,,,,,icNF97.2b
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF98.4c,Cell Line,,,,,,icNF98.4c
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF98.4d,Cell Line,,,,,,icNF98.4d
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF00.10a,Cell Line,,,,,,icNF00.10a
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF04.9a,Cell Line,,,,,,icNF04.9a
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,i28cNF,Cell Line,,,,,,i28cNF
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,i18cNF,Cell Line,,,,,,i18cNF
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,i21cNF,Cell Line,,,,,,i21cNF
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,computational_tool,Genome Analysis Toolkit (GATK),Computational Tool,,,,,,Genome Analysis Toolkit (GATK)
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,cBioPortal,Computational Tool,,,,,,cBioPortal
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,computational_tool,nf-core sarek pipeline (v2.7.1),Computational Tool,,,,,,nf-core sarek pipeline (v2.7.1)
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,computational_tool,DeepVariant,Computational Tool,,,,,,DeepVariant
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,Control-FREEC,Computational Tool,,,,,,Control-FREEC
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,computational_tool,nf-core rnaseq pipeline (v3.5),Computational Tool,,,,,,nf-core rnaseq pipeline (v3.5)
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,Nf1−/− MEFs,Cell Line,,,,,,Nf1−/− MEFs
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,sMPNST cells,Cell Line,,,,,,sMPNST cells
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,cisMPNST cells,Cell Line,,,,,,cisMPNST cells
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,ipNF 04.4 cells,Cell Line,,,,,,ipNF 04.4 cells
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,animal_model,cis Nf1+/−;P53+/− mice,Animal Model,,,,,,cis Nf1+/−;P53+/− mice
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,genetic_reagent,lentiCRISPRv2,Genetic Reagent,,,,,,lentiCRISPRv2
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,genetic_reagent,pBABE vectors,Genetic Reagent,,,,,,pBABE vectors
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,XF24 Extracellular Flux Analyzer,Computational Tool,,,,,,XF24 Extracellular Flux Analyzer
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,LC-MS/MS (Quattro Premier),Computational Tool,,,,,,LC-MS/MS (Quattro Premier)
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,FACSCanto II flow cytometer,Computational Tool,,,,,,FACSCanto II flow cytometer
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,FACSDiva software,Computational Tool,,,,,,FACSDiva software
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,ImageJ software,Computational Tool,,,,,,ImageJ software
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,Origin® 8,Computational Tool,,,,,,Origin® 8
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.9,computational_tool,Ventana-785-Raman spectrometer,Computational Tool,,,,,,Ventana-785-Raman spectrometer
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,clinical_assessment_tool,Wechsler Abbreviated Scale of Intelligence (WASI),Clinical Assessment Tool,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI)
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,clinical_assessment_tool,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",Clinical Assessment Tool,,,,,,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)"
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,clinical_assessment_tool,University of Maryland Letter–Number Sequencing (LNS) task,Clinical Assessment Tool,,,,,,University of Maryland Letter–Number Sequencing (LNS) task
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,clinical_assessment_tool,Spatial capacity working memory (SCAP) task,Clinical Assessment Tool,,,,,,Spatial capacity working memory (SCAP) task
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,computational_tool,FMRIB software library (FSL),Computational Tool,,,,,,FMRIB software library (FSL)
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,computational_tool,SPSS software v. 21,Computational Tool,,,,,,SPSS software v. 21
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,sNF96.2,Cell Line,,,,,,sNF96.2
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,90-8,Cell Line,,,,,,90-8
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,STS-26T,Cell Line,,,,,,STS-26T
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,HS-Sch-2,Cell Line,,,,,,HS-Sch-2
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,CCD-1112Sk,Cell Line,,,,,,CCD-1112Sk
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.9,computational_tool,GAMESS software,Computational Tool,,,,,,GAMESS software
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,computational_tool,Mutiwfn 3.7,Computational Tool,,,,,,Mutiwfn 3.7
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,cell_line,Rosetta2(DE3) competent cells,Cell Line,,,,,,Rosetta2(DE3) competent cells
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,genetic_reagent,HiTrap Chelating Sepharose™ High Performance,Genetic Reagent,,,,,,HiTrap Chelating Sepharose™ High Performance
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,genetic_reagent,Superdex 200 10/300 GL column,Genetic Reagent,,,,,,Superdex 200 10/300 GL column
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,DYNAMIC software,Computational Tool,,,,,,DYNAMIC software
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,computational_tool,Spectra Manager,Computational Tool,,,,,,Spectra Manager
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,Bindworks,Computational Tool,,,,,,Bindworks
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,MantidPlot,Computational Tool,,,,,,MantidPlot
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,animal_model,Nf2 flox2/flox2 mice,Animal Model,,,,,,Nf2 flox2/flox2 mice
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.95,animal_model,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,Animal Model,,,,,,Nf2 flox2/flox2 ;p16 Ink4a*/* mice
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,computational_tool,MATLAB (2019a),Computational Tool,,,,,,MATLAB (2019a)
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,computational_tool,SPM12 (version 7771),Computational Tool,,,,,,SPM12 (version 7771)
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,computational_tool,EEGLAB (version 13.6.5b),Computational Tool,,,,,,EEGLAB (version 13.6.5b)
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.95,clinical_assessment_tool,Vineland Adaptive Behaviour Scale (VABS-III),Clinical Assessment Tool,,,,,,Vineland Adaptive Behaviour Scale (VABS-III)
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,clinical_assessment_tool,adaptive auditory n-back task,Clinical Assessment Tool,,,,,,adaptive auditory n-back task
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,clinical_assessment_tool,non-adaptive visual n-back task,Clinical Assessment Tool,,,,,,non-adaptive visual n-back task
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,computational_tool,SPSS (Version 25),Computational Tool,,,,,,SPSS (Version 25)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,clinical_assessment_tool,Brief Pain Inventory Short Form (BPI-SF),Clinical Assessment Tool,,,,,,Brief Pain Inventory Short Form (BPI-SF)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,clinical_assessment_tool,Patient Health Questionnaire (PHQ),Clinical Assessment Tool,,,,,,Patient Health Questionnaire (PHQ)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,clinical_assessment_tool,Structured Clinical Interview for DSM Self Report version (SCID-SR),Clinical Assessment Tool,,,,,,Structured Clinical Interview for DSM Self Report version (SCID-SR)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,clinical_assessment_tool,Generalized Anxiety Disorder 7 Item version (GAD-7),Clinical Assessment Tool,,,,,,Generalized Anxiety Disorder 7 Item version (GAD-7)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,clinical_assessment_tool,PHQ-9,Clinical Assessment Tool,,,,,,PHQ-9
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,computational_tool,ATLAS.ti (Version 9),Computational Tool,,,,,,ATLAS.ti (Version 9)
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,genetic_reagent,Human Mapping 100K Set,Genetic Reagent,,,,,,Human Mapping 100K Set
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,genetic_reagent,GeneChip Human Genome U133 Plus 2.0 Arrays,Genetic Reagent,,,,,,GeneChip Human Genome U133 Plus 2.0 Arrays
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,HaploReg v2,Computational Tool,,,,,,HaploReg v2
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,limma package,Computational Tool,,,,,,limma package
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,ST8814,Cell Line,,,,,,ST8814
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,ST88-3,Cell Line,,,,,,ST88-3
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,T265p21,Cell Line,,,,,,T265p21
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,S520,Cell Line,,,,,,S520
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,90-8,Cell Line,,,,,,90-8
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,YST1,Cell Line,,,,,,YST1
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,DS-red STS26T cell line,Cell Line,,,,,,DS-red STS26T cell line
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,clinical_assessment_tool,Social Responsiveness Scale 2nd Edition,Clinical Assessment Tool,,,,,,Social Responsiveness Scale 2nd Edition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,clinical_assessment_tool,Autism Diagnostic Observation Scale 2nd Edition,Clinical Assessment Tool,,,,,,Autism Diagnostic Observation Scale 2nd Edition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,clinical_assessment_tool,Autism Diagnostic Interview-Revised,Clinical Assessment Tool,,,,,,Autism Diagnostic Interview-Revised
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,clinical_assessment_tool,WPPSI-IV,Clinical Assessment Tool,,,,,,WPPSI-IV
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,clinical_assessment_tool,WISC-V,Clinical Assessment Tool,,,,,,WISC-V
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,TEA-Ch Sky Search,Clinical Assessment Tool,,,,,,TEA-Ch Sky Search
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,TEA-Ch Score!,Clinical Assessment Tool,,,,,,TEA-Ch Score!
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Shape School,Clinical Assessment Tool,,,,,,Shape School
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II Inhibition,Clinical Assessment Tool,,,,,,NEPSY-II Inhibition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Tower of Hanoi,Clinical Assessment Tool,,,,,,Tower of Hanoi
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,TEA-Ch Creature Counting,Clinical Assessment Tool,,,,,,TEA-Ch Creature Counting
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,WIAT-II Abbreviated,Clinical Assessment Tool,,,,,,WIAT-II Abbreviated
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II Affect Recognition,Clinical Assessment Tool,,,,,,NEPSY-II Affect Recognition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Benton Facial Recognition Test,Clinical Assessment Tool,,,,,,Benton Facial Recognition Test
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II ToM,Clinical Assessment Tool,,,,,,NEPSY-II ToM
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Reading the Mind in the Eyes Test-Child,Clinical Assessment Tool,,,,,,Reading the Mind in the Eyes Test-Child
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Faux Pas Task,Clinical Assessment Tool,,,,,,Faux Pas Task
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Strange Stories,Clinical Assessment Tool,,,,,,Strange Stories
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CELF-Preschool-2,Clinical Assessment Tool,,,,,,CELF-Preschool-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CELF-4 Formulated Sentences,Clinical Assessment Tool,,,,,,CELF-4 Formulated Sentences
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II Comprehension of Instructions,Clinical Assessment Tool,,,,,,NEPSY-II Comprehension of Instructions
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,clinical_assessment_tool,SRS-2,Clinical Assessment Tool,,,,,,SRS-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CADS,Clinical Assessment Tool,,,,,,CADS
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Conners 3,Clinical Assessment Tool,,,,,,Conners 3
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,BRIEF-Preschool,Clinical Assessment Tool,,,,,,BRIEF-Preschool
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,BRIEF,Clinical Assessment Tool,,,,,,BRIEF
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,ABAS-3: 0–5 years,Clinical Assessment Tool,,,,,,ABAS-3: 0–5 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,ABAS-3: 5–21 years,Clinical Assessment Tool,,,,,,ABAS-3: 5–21 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,SSIS Rating Scale,Clinical Assessment Tool,,,,,,SSIS Rating Scale
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Sensory Profile 2,Clinical Assessment Tool,,,,,,Sensory Profile 2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CBCL: 1.5–5 years,Clinical Assessment Tool,,,,,,CBCL: 1.5–5 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CBCL: 6–18 years,Clinical Assessment Tool,,,,,,CBCL: 6–18 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CCC-2,Clinical Assessment Tool,,,,,,CCC-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,clinical_assessment_tool,MEGA-PRESS,Clinical Assessment Tool,,,,,,MEGA-PRESS
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,clinical_assessment_tool,n-back task,Clinical Assessment Tool,,,,,,n-back task
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,clinical_assessment_tool,Corsi block task,Clinical Assessment Tool,,,,,,Corsi block task
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,clinical_assessment_tool,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),Clinical Assessment Tool,,,,,,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV)
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,clinical_assessment_tool,Vineland Adaptive Behavior Scale—third edition,Clinical Assessment Tool,,,,,,Vineland Adaptive Behavior Scale—third edition
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,clinical_assessment_tool,Conners 3 rating scale,Clinical Assessment Tool,,,,,,Conners 3 rating scale
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,computational_tool,SPM12 v7771,Computational Tool,,,,,,SPM12 v7771
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,computational_tool,MATLAB vR2020b,Computational Tool,,,,,,MATLAB vR2020b
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,computational_tool,MRIcroGL,Computational Tool,,,,,,MRIcroGL
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,animal_model,H7;Nf1mut mice,Animal Model,,,,,,H7;Nf1mut mice
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.95,cell_line,hTERT ipNF05.5,Cell Line,,,,,,hTERT ipNF05.5
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,cell_line,hTERT ipn02.3 2λ,Cell Line,,,,,,hTERT ipn02.3 2λ
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,genetic_reagent,NF1 siRNA,Genetic Reagent,,,,,,NF1 siRNA
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,computational_tool,Cell Ranger 5.0.1,Computational Tool,,,,,,Cell Ranger 5.0.1
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,computational_tool,Seurat R package,Computational Tool,,,,,,Seurat R package
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,computational_tool,Proteome Discoverer 2.4,Computational Tool,,,,,,Proteome Discoverer 2.4
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,cell_line,E13.5 DRG neurosphere cells,Cell Line,,,,,,E13.5 DRG neurosphere cells
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.95,clinical_assessment_tool,PlexiQoL,Clinical Assessment Tool,,,,,,PlexiQoL
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.9,clinical_assessment_tool,Nottingham Health Profile (NHP),Clinical Assessment Tool,,,,,,Nottingham Health Profile (NHP)
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.85,computational_tool,SPSS version 28.0,Computational Tool,,,,,,SPSS version 28.0
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,animal_model,Nf1^flox/flox;GFAP-Cre,Animal Model,,,,,,Nf1^flox/flox;GFAP-Cre
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,animal_model,Nf1^flox/mut;GFAP-Cre,Animal Model,,,,,,Nf1^flox/mut;GFAP-Cre
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,cell_line,Daoy,Cell Line,,,,,,Daoy
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.85,cell_line,GL261,Cell Line,,,,,,GL261
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.8,cell_line,GL261-luc,Cell Line,,,,,,GL261-luc
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,genetic_reagent,CRISPR-CAS9,Genetic Reagent,,,,,,CRISPR-CAS9
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,genetic_reagent,shRNA,Genetic Reagent,,,,,,shRNA
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,cell_line,NF1-/- iPSC-derived neural crest cells,Cell Line,,,,,,NF1-/- iPSC-derived neural crest cells
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,advanced_cellular_model,neurofibromasphere model,Advanced Cellular Model,,,,,,neurofibromasphere model
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,bwa mem,Computational Tool,,,,,,bwa mem
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,computational_tool,Salmon v1.8.0,Computational Tool,,,,,,Salmon v1.8.0
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"PAM71 (MedChemExpress, catalog HY-134494)",Genetic Reagent,,,,,,"PAM71 (MedChemExpress, catalog HY-134494)"
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,animal_model,DhhCre mice,Animal Model,,,,,,DhhCre mice
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,animal_model,Nf1flox/flox;PostnCre+ mice,Animal Model,,,,,,Nf1flox/flox;PostnCre+ mice
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,animal_model,Nf1flox/flox;Arf flox/flox;PostnCre+ mice,Animal Model,,,,,,Nf1flox/flox;Arf flox/flox;PostnCre+ mice
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,JH-2-002 cell line,Cell Line,,,,,,JH-2-002 cell line
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,JH-2-103 cell line,Cell Line,,,,,,JH-2-103 cell line
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,ST-8814 cell line,Cell Line,,,,,,ST-8814 cell line
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,S462 cell line,Cell Line,,,,,,S462 cell line
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,cell_line,hTERT ipn02.3 2λ cell line,Cell Line,,,,,,hTERT ipn02.3 2λ cell line
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,cell_line,hTERT NF1 ipNF95.6 cell line,Cell Line,,,,,,hTERT NF1 ipNF95.6 cell line
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,nCounter Sprint Profiler,Computational Tool,,,,,,nCounter Sprint Profiler
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,nSolver Advanced Analysis Software version 4.0,Computational Tool,,,,,,nSolver Advanced Analysis Software version 4.0
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,Omics Playground v2.7.18,Computational Tool,,,,,,Omics Playground v2.7.18
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,UCSC Xena browser,Computational Tool,,,,,,UCSC Xena browser
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,IDEP.92,Computational Tool,,,,,,IDEP.92
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,ComplexHeatmap R/Bioconductor package,Computational Tool,,,,,,ComplexHeatmap R/Bioconductor package
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,Scanpy,Computational Tool,,,,,,Scanpy
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,computational_tool,infercnvpy package,Computational Tool,,,,,,infercnvpy package
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,HALO Image Analysis software version 2.0.5,Computational Tool,,,,,,HALO Image Analysis software version 2.0.5
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,minfi,Computational Tool,,,,,,minfi
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,,ConsensusClusterPlus
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Rtsne,Computational Tool,,,,,,Rtsne
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,conumee,Computational Tool,,,,,,conumee
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Haplotype Caller,Computational Tool,,,,,,Haplotype Caller
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,MuTect1,Computational Tool,,,,,,MuTect1
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Variant Effect Predictor,Computational Tool,,,,,,Variant Effect Predictor
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Sequenza,Computational Tool,,,,,,Sequenza
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,BwaMem,Computational Tool,,,,,,BwaMem
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,MAVIS,Computational Tool,,,,,,MAVIS
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,FusionCatcher,Computational Tool,,,,,,FusionCatcher
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,FastQC,Computational Tool,,,,,,FastQC
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,STAR aligner,Computational Tool,,,,,,STAR aligner
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,AutoAnnotate,Computational Tool,,,,,,AutoAnnotate
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Enrichment Map,Computational Tool,,,,,,Enrichment Map
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,CIBERSORT,Computational Tool,,,,,,CIBERSORT
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,BWA MEM,Computational Tool,,,,,,BWA MEM
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,GeneMapper software,Computational Tool,,,,,,GeneMapper software
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1+/− mice,Animal Model,,,,,,Nf1+/− mice
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/wt mice,Animal Model,,,,,,Nf1flox/wt mice
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/mut mice,Animal Model,,,,,,Nf1flox/mut mice
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/flox; Olig2-Cre mice,Animal Model,,,,,,Nf1flox/flox; Olig2-Cre mice
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/flox mice,Animal Model,,,,,,Nf1flox/flox mice
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/flox; Prom1-CreER mice,Animal Model,,,,,,Nf1flox/flox; Prom1-CreER mice
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.95,animal_model,Nf1flox/flox;PostnCre+ mice,Animal Model,,,,,,Nf1flox/flox;PostnCre+ mice
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.8,genetic_reagent,Kit Ligand,Genetic Reagent,,,,,,Kit Ligand
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,computational_tool,Agilent 1200 HPLC,Computational Tool,,,,,,Agilent 1200 HPLC
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,computational_tool,ABI 3200 MS/MS,Computational Tool,,,,,,ABI 3200 MS/MS
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,computational_tool,GraphPad Prism 5.0,Computational Tool,,,,,,GraphPad Prism 5.0
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,computational_tool,GraphPad Prism 6.0,Computational Tool,,,,,,GraphPad Prism 6.0
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,cell_line,"M14 (ST88-14, RRID:CVCL_8916)",Cell Line,,,,,,"M14 (ST88-14, RRID:CVCL_8916)"
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,cell_line,M10 (MPNST1),Cell Line,,,,,,M10 (MPNST1)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M1,Cell Line,,,,,,M1
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M3,Cell Line,,,,,,M3
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M4,Cell Line,,,,,,M4
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M6,Cell Line,,,,,,M6
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,animal_model,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,Animal Model,,,,,,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,cell_line,"HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063)",Cell Line,,,,,,"HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063)"
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,genetic_reagent,"psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260)",Genetic Reagent,,,,,,"psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260)"
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,FastQC (RRID:SCR_014583),Computational Tool,,,,,,FastQC (RRID:SCR_014583)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,patient_derived_model,MPNST PDX-1,Patient-Derived Model,,,,,,MPNST PDX-1
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,TrimGalore (RRID:SCR_011847),Computational Tool,,,,,,TrimGalore (RRID:SCR_011847)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,STAR v2.6 (RRID:SCR_004463),Computational Tool,,,,,,STAR v2.6 (RRID:SCR_004463)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,HTSeq v0.9.1 (RRID:SCR_005514),Computational Tool,,,,,,HTSeq v0.9.1 (RRID:SCR_005514)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,deepTools v3.1 (RRID:SCR_016366),Computational Tool,,,,,,deepTools v3.1 (RRID:SCR_016366)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,Homer v4.5 (RRID:SCR_010881),Computational Tool,,,,,,Homer v4.5 (RRID:SCR_010881)
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"featureCounts (v1.5.0-p1, RRID:SCR_012919)",Computational Tool,,,,,,"featureCounts (v1.5.0-p1, RRID:SCR_012919)"
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"pheatmap (v.1.0.12, RRID:SCR_016418)",Computational Tool,,,,,,"pheatmap (v.1.0.12, RRID:SCR_016418)"
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Computational Tool,,,,,,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)"
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,Integrative Genomics Viewer,Computational Tool,,,,,,Integrative Genomics Viewer
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Computational Tool,,,,,,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)"
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipnNF95.11C,Cell Line,,,,,,ipnNF95.11C
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF05.5-MX,Cell Line,,,,,,ipNF05.5-MX
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF06.2A,Cell Line,,,,,,ipNF06.2A
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF95.11b C/T,Cell Line,,,,,,ipNF95.11b C/T
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF95.6,Cell Line,,,,,,ipNF95.6
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,cell_line,ipNF02.3 2λ,Cell Line,,,,,,ipNF02.3 2λ
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,cell_line,ipNF02.8,Cell Line,,,,,,ipNF02.8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,computational_tool,Synapse,Computational Tool,,,,,,Synapse
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.95,computational_tool,RENOVO-NF1,Computational Tool,,,,,,RENOVO-NF1
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,ClinVar,Computational Tool,,,,,,ClinVar
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,Mutation Taster,Computational Tool,,,,,,Mutation Taster
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,HGMD,Computational Tool,,,,,,HGMD
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,LOVD,Computational Tool,,,,,,LOVD
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,PolyPhen-2,Computational Tool,,,,,,PolyPhen-2
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,Human Splicing Finder,Computational Tool,,,,,,Human Splicing Finder
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,ESE Finder,Computational Tool,,,,,,ESE Finder
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,GnomAD,Computational Tool,,,,,,GnomAD
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,1000 Genomes,Computational Tool,,,,,,1000 Genomes
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.85,computational_tool,cutpointR,Computational Tool,,,,,,cutpointR
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.95,animal_model,Nf1 fl/+,Animal Model,,,,,,Nf1 fl/+
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.85,clinical_assessment_tool,Rotarod,Clinical Assessment Tool,,,,,,Rotarod
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,computational_tool,ExplorDTI,Computational Tool,,,,,,ExplorDTI
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,computational_tool,Advanced Normalization Tools (ANTs),Computational Tool,,,,,,Advanced Normalization Tools (ANTs)
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.95,computational_tool,NF Research Tools Database,Computational Tool,,,,,,NF Research Tools Database
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,computational_tool,JSON-LD schema,Computational Tool,,,,,,JSON-LD schema
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.9,computational_tool,Synapse collaborative science platform,Computational Tool,,,,,,Synapse collaborative science platform
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.95,advanced_cellular_model,cNF organoids,Advanced Cellular Model,,,,,,cNF organoids
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,patient_derived_model,Cutaneous neurofibroma samples,Patient-Derived Model,,,,,,Cutaneous neurofibroma samples
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,Salmon v1.4,Computational Tool,,,,,,Salmon v1.4
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,BWA-MEM2 v2.1,Computational Tool,,,,,,BWA-MEM2 v2.1
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,GATK v4.1.9.0,Computational Tool,,,,,,GATK v4.1.9.0
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,MCP-Counter,Computational Tool,,,,,,MCP-Counter
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,BSBolt,Computational Tool,,,,,,BSBolt
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,metilene v0.2-8,Computational Tool,,,,,,metilene v0.2-8
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,DELLY v1.1.3,Computational Tool,,,,,,DELLY v1.1.3
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,InterVar,Computational Tool,,,,,,InterVar
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.85,computational_tool,rare disease workflows,Computational Tool,,,,,,rare disease workflows
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,cNFOrganoidAnalysis,Computational Tool,,,,,,cNFOrganoidAnalysis
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,minfi,Computational Tool,,,,,,minfi
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,,ConsensusClusterPlus
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Genome Analysis Toolkit (GATK),Computational Tool,,,,,,Genome Analysis Toolkit (GATK)
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,CellRanger,Computational Tool,,,,,,CellRanger
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Seurat,Computational Tool,,,,,,Seurat
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Clustree,Computational Tool,,,,,,Clustree
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,InferCNV,Computational Tool,,,,,,InferCNV
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,NF95.11b,Cell Line,,,,,,NF95.11b
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,NF95.6,Cell Line,,,,,,NF95.6
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,SNF02.2,Cell Line,,,,,,SNF02.2
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,SNF94.3,Cell Line,,,,,,SNF94.3
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,SNF96.2,Cell Line,,,,,,SNF96.2
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,cell_line,JW18.2,Cell Line,,,,,,JW18.2
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,cell_line,JW23.3,Cell Line,,,,,,JW23.3
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,animal_model,Periostin-CRE;NF2 fl/fl,Animal Model,,,,,,Periostin-CRE;NF2 fl/fl
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.85,animal_model,P0-CRE,Animal Model,,,,,,P0-CRE
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,cell_line,BenMen-1,Cell Line,,,,,,BenMen-1
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,cell_line,KT21-MG1,Cell Line,,,,,,KT21-MG1
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.85,cell_line,293FT,Cell Line,,,,,,293FT
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,clinical_assessment_tool,WAIS-III,Clinical Assessment Tool,,,,,,WAIS-III
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,clinical_assessment_tool,WISC-III,Clinical Assessment Tool,,,,,,WISC-III
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Nine-Hole Peg Test,Clinical Assessment Tool,,,,,,Nine-Hole Peg Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Rey-Osterrieth Complex Figure Test,Clinical Assessment Tool,,,,,,Rey-Osterrieth Complex Figure Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Rey Auditory-Verbal Learning Test (RAVLT),Clinical Assessment Tool,,,,,,Rey Auditory-Verbal Learning Test (RAVLT)
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Category Fluency Test,Clinical Assessment Tool,,,,,,Category Fluency Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Lexical Fluency Test,Clinical Assessment Tool,,,,,,Lexical Fluency Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Five Digits Test (FDT),Clinical Assessment Tool,,,,,,Five Digits Test (FDT)
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Corsi block-tapping task,Clinical Assessment Tool,,,,,,Corsi block-tapping task
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Tower of London Test,Clinical Assessment Tool,,,,,,Tower of London Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,computational_tool,Statistical Parametric Mapping toolbox (SPM8),Computational Tool,,,,,,Statistical Parametric Mapping toolbox (SPM8)
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,computational_tool,Matlab 7.12.0,Computational Tool,,,,,,Matlab 7.12.0
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,computational_tool,kernlab R library,Computational Tool,,,,,,kernlab R library
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,GE Discovery 690,Clinical Assessment Tool,,,,,,GE Discovery 690
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,PLIER,Computational Tool,,,,,,PLIER
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,vcf2maf,Computational Tool,,,,,,vcf2maf
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,MultiPLIER,Computational Tool,,,,,,MultiPLIER
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,caret,Computational Tool,,,,,,caret
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,CIBERSORT,Computational Tool,,,,,,CIBERSORT
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,MCP-counter,Computational Tool,,,,,,MCP-counter
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,metaVIPER,Computational Tool,,,,,,metaVIPER
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,pheatmap,Computational Tool,,,,,,pheatmap
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,NF Data Portal,Computational Tool,,,,,,NF Data Portal
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,R 4.0.3,Computational Tool,,,,,,R 4.0.3
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,computational_tool,WGCNA,Computational Tool,,,,,,WGCNA
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,miRTarBase,Computational Tool,,,,,,miRTarBase
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,connectivity map (CMap),Computational Tool,,,,,,connectivity map (CMap)
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.95,clinical_assessment_tool,UK NF2 Genetic Severity Score,Clinical Assessment Tool,,,,,,UK NF2 Genetic Severity Score
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.9,clinical_assessment_tool,8-item NF2 disease-specific quality of life score,Clinical Assessment Tool,,,,,,8-item NF2 disease-specific quality of life score
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,clinical_assessment_tool,hearing grade score,Clinical Assessment Tool,,,,,,hearing grade score
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.8,computational_tool,SPSS V.23,Computational Tool,,,,,,SPSS V.23
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,clinical_assessment_tool,Manchester NF2 diagnostic criteria,Clinical Assessment Tool,,,,,,Manchester NF2 diagnostic criteria
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,cell_line,U251,Cell Line,,,,,,U251
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,I2HCP panel,Genetic Reagent,,,,,,I2HCP panel
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,computational_tool,CLC-workbench,Computational Tool,,,,,,CLC-workbench
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,computational_tool,PredictProtein,Computational Tool,,,,,,PredictProtein
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,Endo-Porter,Genetic Reagent,,,,,,Endo-Porter
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,genetic_reagent,Gateway Gene Cloning system,Genetic Reagent,,,,,,Gateway Gene Cloning system
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,cell_line,HeLa cells,Cell Line,,,,,,HeLa cells
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,computational_tool,GraphPad Prism software v7,Computational Tool,,,,,,GraphPad Prism software v7
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,cell_line,NF2 primary fibroblasts,Cell Line,,,,,,NF2 primary fibroblasts
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,animal_model,Postn-cre;Nf2f/f,Animal Model,,,,,,Postn-cre;Nf2f/f
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,clinical_assessment_tool,Noldus Cat-Walk XT system,Clinical Assessment Tool,,,,,,Noldus Cat-Walk XT system
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,cell_line,Primary human vestibular schwannoma (VS) cell cultures,Cell Line,,,,,,Primary human vestibular schwannoma (VS) cell cultures
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,cell_line,NF90-8,Cell Line,,,,,,NF90-8
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,cell_line,Primary normal rat Schwann cells,Cell Line,,,,,,Primary normal rat Schwann cells
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,cell_line,iSC,Cell Line,,,,,,iSC
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,Zpr-1,Antibody,,,,,,Zpr-1
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,Zn-5,Antibody,,,,,,Zn-5
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,computational_tool,CRISPRscan,Computational Tool,,,,,,CRISPRscan
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,computational_tool,"MATLAB (R2008a, MathWorks, Natick, MA, USA)",Computational Tool,,,,,,"MATLAB (R2008a, MathWorks, Natick, MA, USA)"
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,computational_tool,"STIM 2 (Neuroscan, Charlotte, NC, USA)",Computational Tool,,,,,,"STIM 2 (Neuroscan, Charlotte, NC, USA)"
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,computational_tool,Scan 4.5 (Neuroscan),Computational Tool,,,,,,Scan 4.5 (Neuroscan)
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.95,clinical_assessment_tool,Wechsler Intelligence Scale for Children (WISC-III),Clinical Assessment Tool,,,,,,Wechsler Intelligence Scale for Children (WISC-III)
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,computational_tool,"IBM SPSS Statistics, version 19",Computational Tool,,,,,,"IBM SPSS Statistics, version 19"
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.75,clinical_assessment_tool,Diamond Digital color monitor (Mitsubishi Electric Australia),Clinical Assessment Tool,,,,,,Diamond Digital color monitor (Mitsubishi Electric Australia)
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,cell_line,C6 cells,Cell Line,,,,,,C6 cells
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.8,computational_tool,MATLAB software,Computational Tool,,,,,,MATLAB software
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,computational_tool,WGCNA package v1.69,Computational Tool,,,,,,WGCNA package v1.69
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipNF95.11bC,Cell Line,,,,,,ipNF95.11bC
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipnNF95.11c,Cell Line,,,,,,ipnNF95.11c
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipNF05.5 Single Clone,Cell Line,,,,,,ipNF05.5 Single Clone
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipNF05.5 Mixed Clones,Cell Line,,,,,,ipNF05.5 Mixed Clones
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,animal_model,DhhCre;Nf1f/f;Luciferase,Animal Model,,,,,,DhhCre;Nf1f/f;Luciferase
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,computational_tool,SynergyFinder,Computational Tool,,,,,,SynergyFinder
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,NPcis (Stock #008191),Animal Model,,,,,,NPcis (Stock #008191)
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,Nf1 (#017640),Animal Model,,,,,,Nf1 (#017640)
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,computational_tool,STAR aligner,Computational Tool,,,,,,STAR aligner
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Leiden Open Variation Database (LOVD),Computational Tool,,,,,,Leiden Open Variation Database (LOVD)
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,ClinVar NCBI,Computational Tool,,,,,,ClinVar NCBI
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Human Gene Mutation Database (HGMD),Computational Tool,,,,,,Human Gene Mutation Database (HGMD)
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Clinical Interpretation of Variants in Cancer (CIViC),Computational Tool,,,,,,Clinical Interpretation of Variants in Cancer (CIViC)
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Mastermind Genomic Search Engine,Computational Tool,,,,,,Mastermind Genomic Search Engine
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,computational_tool,Alamut Visual version 2.15,Computational Tool,,,,,,Alamut Visual version 2.15
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Align-GVGD,Computational Tool,,,,,,Align-GVGD
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,SIFT,Computational Tool,,,,,,SIFT
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,PolyPhen-2,Computational Tool,,,,,,PolyPhen-2
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,computational_tool,gnomAD v2.1.1,Computational Tool,,,,,,gnomAD v2.1.1
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,UCSC LiftOver tool,Computational Tool,,,,,,UCSC LiftOver tool
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,alleleFrequencyApp,Computational Tool,,,,,,alleleFrequencyApp
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,COSMIC,Computational Tool,,,,,,COSMIC
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,CanVar-UK cancer predisposition gene variant database,Computational Tool,,,,,,CanVar-UK cancer predisposition gene variant database
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,clinical_assessment_tool,Manchester Criteria,Clinical Assessment Tool,,,,,,Manchester Criteria
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,patient_derived_model,human neurofibroma xenografts,Patient-Derived Model,,,,,,human neurofibroma xenografts
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.95,animal_model,Nf1+/− GFAP CKO mice,Animal Model,,,,,,Nf1+/− GFAP CKO mice
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,animal_model,Nf1 flox/flox mice,Animal Model,,,,,,Nf1 flox/flox mice
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,computational_tool,Beta Imager 2000Z Digital Beta Imaging System,Computational Tool,,,,,,Beta Imager 2000Z Digital Beta Imaging System
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,computational_tool,Siemens Focus F220,Computational Tool,,,,,,Siemens Focus F220
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.85,clinical_assessment_tool,MC-780MA Tanita Tokyo body composition analyzer,Clinical Assessment Tool,,,,,,MC-780MA Tanita Tokyo body composition analyzer
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.8,clinical_assessment_tool,Citec hand-held dynamometer,Clinical Assessment Tool,,,,,,Citec hand-held dynamometer
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.9,clinical_assessment_tool,Handwriting Speed Test,Clinical Assessment Tool,,,,,,Handwriting Speed Test
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,6-minute-walk test,Clinical Assessment Tool,,,,,,6-minute-walk test
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,PedsQL Generic 4.0,Clinical Assessment Tool,,,,,,PedsQL Generic 4.0
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,PedsQL Neuromuscular 3.0,Clinical Assessment Tool,,,,,,PedsQL Neuromuscular 3.0
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,CBCL/6-18,Clinical Assessment Tool,,,,,,CBCL/6-18
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,antibody,"DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies)",Antibody,,,,,,"DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies)"
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Illumina bcl2fastq v1.8.4 software,Computational Tool,,,,,,Illumina bcl2fastq v1.8.4 software
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Burrows-Wheeler Aligner v0.7.10,Computational Tool,,,,,,Burrows-Wheeler Aligner v0.7.10
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Picard Tools v1.119,Computational Tool,,,,,,Picard Tools v1.119
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,MDLVC v5.0,Computational Tool,,,,,,MDLVC v5.0
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,HaplotypeCaller (Genome Analysis Tool Kit 3.3),Computational Tool,,,,,,HaplotypeCaller (Genome Analysis Tool Kit 3.3)
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Integrated Genomics Viewer v2.3.4 (IGV),Computational Tool,,,,,,Integrated Genomics Viewer v2.3.4 (IGV)
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,GraphPad Prism version 8.0,Computational Tool,,,,,,GraphPad Prism version 8.0
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,SAS version 9.4,Computational Tool,,,,,,SAS version 9.4
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,R version 3.3.2,Computational Tool,,,,,,R version 3.3.2
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,clinical_assessment_tool,Wechsler Intelligence Scale,Clinical Assessment Tool,,,,,,Wechsler Intelligence Scale
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,clinical_assessment_tool,A Developmental NEuroPSYchological Assessment (NEPSY-II),Clinical Assessment Tool,,,,,,A Developmental NEuroPSYchological Assessment (NEPSY-II)
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,computational_tool,melodic v3.15,Computational Tool,,,,,,melodic v3.15
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,computational_tool,fMRI Expert Analysis Tool (FEAT),Computational Tool,,,,,,fMRI Expert Analysis Tool (FEAT)
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,computational_tool,Multiple Imputation by Chained Equations (MICE),Computational Tool,,,,,,Multiple Imputation by Chained Equations (MICE)
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,clinical_assessment_tool,Tanner staging,Clinical Assessment Tool,,,,,,Tanner staging
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,clinical_assessment_tool,Numeric Rating Scale-11,Clinical Assessment Tool,,,,,,Numeric Rating Scale-11
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,clinical_assessment_tool,Pain Interference Index,Clinical Assessment Tool,,,,,,Pain Interference Index
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,clinical_assessment_tool,NRS-11,Clinical Assessment Tool,,,,,,NRS-11
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,clinical_assessment_tool,PII,Clinical Assessment Tool,,,,,,PII
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,clinical_assessment_tool,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),Clinical Assessment Tool,,,,,,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,clinical_assessment_tool,Pain Interference Index for plexiform neurofibromas (PII-pNF),Clinical Assessment Tool,,,,,,Pain Interference Index for plexiform neurofibromas (PII-pNF)
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.95,clinical_assessment_tool,PedsQL 4.0 Generic Core Scales,Clinical Assessment Tool,,,,,,PedsQL 4.0 Generic Core Scales
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.75,clinical_assessment_tool,HPLC/MS/MS method,Clinical Assessment Tool,,,,,,HPLC/MS/MS method
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.95,animal_model,Tg(U6x:nf2a/b-4sgRNA),Animal Model,,,,,,Tg(U6x:nf2a/b-4sgRNA)
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,computational_tool,CHOP-CHOP,Computational Tool,,,,,,CHOP-CHOP
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,computational_tool,CRISPResso2,Computational Tool,,,,,,CRISPResso2
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Cellpose,Computational Tool,,,,,,Cellpose
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Trimmomatic v 0.39,Computational Tool,,,,,,Trimmomatic v 0.39
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,BWA-MEM,Computational Tool,,,,,,BWA-MEM
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,GATK V4.2,Computational Tool,,,,,,GATK V4.2
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Xenosplit,Computational Tool,,,,,,Xenosplit
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,Pindel,Computational Tool,,,,,,Pindel
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Variant Effect Predictor (VEP),Computational Tool,,,,,,Variant Effect Predictor (VEP)
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,maftools v2.10.0,Computational Tool,,,,,,maftools v2.10.0
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,CNVkit V2.0,Computational Tool,,,,,,CNVkit V2.0
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,DESeq2 package,Computational Tool,,,,,,DESeq2 package
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,advanced_cellular_model,3D microtissues,Advanced Cellular Model,,,,,,3D microtissues
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,patient_derived_model,NF1-associated MPNST-PDX,Patient-Derived Model,,,,,,NF1-associated MPNST-PDX
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,computational_tool,GEOquery,Computational Tool,,,,,,GEOquery
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,computational_tool,Biobase,Computational Tool,,,,,,Biobase
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.95,computational_tool,Seurat,Computational Tool,,,,,,Seurat
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,computational_tool,Slingshot,Computational Tool,,,,,,Slingshot
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,clinical_assessment_tool,H-score,Clinical Assessment Tool,,,,,,H-score
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,SF-36,Clinical Assessment Tool,,,,,,SF-36
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,EQ-5D-5L,Clinical Assessment Tool,,,,,,EQ-5D-5L
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,PROMIS pain interference short form 8a,Clinical Assessment Tool,,,,,,PROMIS pain interference short form 8a
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,PedsQL NF1 adult module,Clinical Assessment Tool,,,,,,PedsQL NF1 adult module
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,NFTI-QOL,Clinical Assessment Tool,,,,,,NFTI-QOL
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,clinical_assessment_tool,Ablon visibility index,Clinical Assessment Tool,,,,,,Ablon visibility index
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,clinical_assessment_tool,House and Brackmann facial nerve scale,Clinical Assessment Tool,,,,,,House and Brackmann facial nerve scale
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.85,computational_tool,R statistical software version 3.5.1,Computational Tool,,,,,,R statistical software version 3.5.1
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,CellRanger,Computational Tool,,,,,,CellRanger
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,computational_tool,Seurat 3.1.0,Computational Tool,,,,,,Seurat 3.1.0
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,CellChatDB,Computational Tool,,,,,,CellChatDB
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,Space Ranger,Computational Tool,,,,,,Space Ranger
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,computational_tool,Seurat v4.0.1,Computational Tool,,,,,,Seurat v4.0.1
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,Clustree,Computational Tool,,,,,,Clustree
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,computational_tool,R Studio PKNCA package (version 0.9.3),Computational Tool,,,,,,R Studio PKNCA package (version 0.9.3)
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Ras activation assay (Millipore),Clinical Assessment Tool,,,,,,Ras activation assay (Millipore)
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,cAMP assay (New East Biosciences),Clinical Assessment Tool,,,,,,cAMP assay (New East Biosciences)
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,TUNEL assay (Roche Diagnostics),Clinical Assessment Tool,,,,,,TUNEL assay (Roche Diagnostics)
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,dopamine assay (Rocky Mountain Diagnostics),Clinical Assessment Tool,,,,,,dopamine assay (Rocky Mountain Diagnostics)
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Morris Water Maze,Clinical Assessment Tool,,,,,,Morris Water Maze
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,clinical_assessment_tool,virtual optokinetic system (VOS),Clinical Assessment Tool,,,,,,virtual optokinetic system (VOS)
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,cell_line,MOLM-13,Cell Line,,,,,,MOLM-13
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,genetic_reagent,pCW57.1,Genetic Reagent,,,,,,pCW57.1
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,cell_line,293T lenti-X cells,Cell Line,,,,,,293T lenti-X cells
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,animal_model,Osx-/- Nf1flox/flox mice,Animal Model,,,,,,Osx-/- Nf1flox/flox mice
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,animal_model,"Osx-tTA,tetO-cre;Nf1flox/flox mice",Animal Model,,,,,,"Osx-tTA,tetO-cre;Nf1flox/flox mice"
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,cell_line,Nf1flox/flox bone marrow stromal cells,Cell Line,,,,,,Nf1flox/flox bone marrow stromal cells
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,clinical_assessment_tool,Cogstate,Clinical Assessment Tool,,,,,,Cogstate
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,clinical_assessment_tool,BRIEF,Clinical Assessment Tool,,,,,,BRIEF
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.85,clinical_assessment_tool,Behavior Rating Inventory of Executive Function,Clinical Assessment Tool,,,,,,Behavior Rating Inventory of Executive Function
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,animal_model,Nf2 mice,Animal Model,,,,,,Nf2 mice
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,advanced_cellular_model,BioCoat Matrigel invasion chambers (Becton Dickinson),Advanced Cellular Model,,,,,,BioCoat Matrigel invasion chambers (Becton Dickinson)
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,computational_tool,STAR mapper (Version 2.4.1d),Computational Tool,,,,,,STAR mapper (Version 2.4.1d)
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,computational_tool,Picard tools,Computational Tool,,,,,,Picard tools
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.95,computational_tool,QURNAs,Computational Tool,,,,,,QURNAs
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,computational_tool,Alamut v2.15 (Interactive Biosoftware),Computational Tool,,,,,,Alamut v2.15 (Interactive Biosoftware)
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,genetic_reagent,IGT-T192V1 Plus panel,Genetic Reagent,,,,,,IGT-T192V1 Plus panel
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,Burrows-Wheeler Aligner (bwa-0.7.15),Computational Tool,,,,,,Burrows-Wheeler Aligner (bwa-0.7.15)
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,Sambamba (v0.6.6),Computational Tool,,,,,,Sambamba (v0.6.6)
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,Genome Analysis Toolkit (GATK),Computational Tool,,,,,,Genome Analysis Toolkit (GATK)
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,computational_tool,CASAVA v1.82,Computational Tool,,,,,,CASAVA v1.82
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,computational_tool,Leiden Open Variation Database (LOVD),Computational Tool,,,,,,Leiden Open Variation Database (LOVD)
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,PLINK,Computational Tool,,,,,,PLINK
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,computational_tool,SNP & Variation Suite v8.3.4,Computational Tool,,,,,,SNP & Variation Suite v8.3.4
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,EMMAX,Computational Tool,,,,,,EMMAX
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,METAL,Computational Tool,,,,,,METAL
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,ComPaSS-GWAS,Computational Tool,,,,,,ComPaSS-GWAS
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,computational_tool,Haploview 4.2,Computational Tool,,,,,,Haploview 4.2
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,GTEx,Computational Tool,,,,,,GTEx
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Wood's lamp,Clinical Assessment Tool,,,,,,Wood's lamp
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,cell_line,DH5α bacteria,Cell Line,,,,,,DH5α bacteria
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,Adobe Photoshop CS2,Computational Tool,,,,,,Adobe Photoshop CS2
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,computational_tool,Peak Scanner software from Applied Biosystems,Computational Tool,,,,,,Peak Scanner software from Applied Biosystems
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,SDS3.0,Computational Tool,,,,,,SDS3.0
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,computational_tool,COSMIC Database,Computational Tool,,,,,,COSMIC Database
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,Prizm v.4 (GraphPad),Computational Tool,,,,,,Prizm v.4 (GraphPad)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD3,Antibody,,,,,,CD3
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD8,Antibody,,,,,,CD8
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD11c,Antibody,,,,,,CD11c
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD19,Antibody,,,,,,CD19
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD163,Antibody,,,,,,CD163
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CSF1R,Antibody,,,,,,CSF1R
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,FOXP3,Antibody,,,,,,FOXP3
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,PD-L1,Antibody,,,,,,PD-L1
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,nf-core/rnaseq (v3.11.2),Computational Tool,,,,,,nf-core/rnaseq (v3.11.2)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,salmon (v1.10.1),Computational Tool,,,,,,salmon (v1.10.1)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,sva R package (v3.42.0),Computational Tool,,,,,,sva R package (v3.42.0)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,immunedeconv (v2.1.0),Computational Tool,,,,,,immunedeconv (v2.1.0)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,ggplot2 (v3.4.4),Computational Tool,,,,,,ggplot2 (v3.4.4)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,ggridges (v0.5.5),Computational Tool,,,,,,ggridges (v0.5.5)
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,HALO imaging analysis software,Computational Tool,,,,,,HALO imaging analysis software
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,clinical_assessment_tool,Wechsler Intelligence Scales,Clinical Assessment Tool,,,,,,Wechsler Intelligence Scales
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.9,computational_tool,FreeSurfer,Computational Tool,,,,,,FreeSurfer
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.75,computational_tool,RStudio,Computational Tool,,,,,,RStudio
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,cell_line,mouse embryonic fibroblasts (MEFs),Cell Line,,,,,,mouse embryonic fibroblasts (MEFs)
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,cell_line,tail-tip fibroblasts (TTFs),Cell Line,,,,,,tail-tip fibroblasts (TTFs)
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.95,advanced_cellular_model,NF1 patient-derived induced pluripotent stem cells (iPSCs),Advanced Cellular Model,,,,,,NF1 patient-derived induced pluripotent stem cells (iPSCs)
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,animal_model,Nf1+/- mice,Animal Model,,,,,,Nf1+/- mice
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,cell_line,Neural stem cells,Cell Line,,,,,,Neural stem cells
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,animal_model,Nf2flox/flox mice,Animal Model,,,,,,Nf2flox/flox mice
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,genetic_reagent,MSCV,Genetic Reagent,,,,,,MSCV
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,genetic_reagent,Rac1 N17,Genetic Reagent,,,,,,Rac1 N17
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,computational_tool,GraphPad Prism 5.0,Computational Tool,,,,,,GraphPad Prism 5.0
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,cell_line,Nf2-deficient spinal cord neural progenitor cells,Cell Line,,,,,,Nf2-deficient spinal cord neural progenitor cells
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,Nf1 flox/flox mice,Animal Model,,,,,,Nf1 flox/flox mice
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Rotarod apparatus,Clinical Assessment Tool,,,,,,Rotarod apparatus
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,cell_line,BL21 (DE3) E.coli,Cell Line,,,,,,BL21 (DE3) E.coli
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,H929,Cell Line,,,,,,H929
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,U266B1,Cell Line,,,,,,U266B1
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,U2932,Cell Line,,,,,,U2932
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,MCF7,Cell Line,,,,,,MCF7
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,HT229,Cell Line,,,,,,HT229
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,HCC1937,Cell Line,,,,,,HCC1937
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,FACSDiva v6.1,Computational Tool,,,,,,FACSDiva v6.1
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,FlowJo software v10.0.8,Computational Tool,,,,,,FlowJo software v10.0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,GraphPad Prism v8.3,Computational Tool,,,,,,GraphPad Prism v8.3
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,HALO image analysis software v3.2,Computational Tool,,,,,,HALO image analysis software v3.2
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,ZEN imaging software v2.3,Computational Tool,,,,,,ZEN imaging software v2.3
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,cell_line,NSF1,Cell Line,,,,,,NSF1
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.8,cell_line,BRGN,Cell Line,,,,,,BRGN
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,cell_line,primary human Schwann cells (HSC),Cell Line,,,,,,primary human Schwann cells (HSC)
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,computational_tool,CLC Genomics Workbench 22,Computational Tool,,,,,,CLC Genomics Workbench 22
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,computational_tool,CosinorPy Python package,Computational Tool,,,,,,CosinorPy Python package
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.95,animal_model,Nf1 (+/-),Animal Model,,,,,,Nf1 (+/-)
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,genetic_reagent,Alexa Fluor 594-labeled dextrans,Genetic Reagent,,,,,,Alexa Fluor 594-labeled dextrans
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,computational_tool,pCLAMP 9.2,Computational Tool,,,,,,pCLAMP 9.2
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,computational_tool,Volocity 4.2,Computational Tool,,,,,,Volocity 4.2
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,computational_tool,ImageJ 1.46,Computational Tool,,,,,,ImageJ 1.46
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,computational_tool,Igor 6.22A,Computational Tool,,,,,,Igor 6.22A
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,computational_tool,NeuroMatic,Computational Tool,,,,,,NeuroMatic
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.95,patient_derived_model,NF1-MPNST patient-derived xenografts,Patient-Derived Model,,,,,,NF1-MPNST patient-derived xenografts
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Trim Galore,Computational Tool,,,,,,Trim Galore
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,BWA-MEM,Computational Tool,,,,,,BWA-MEM
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Disambiguate v1.0,Computational Tool,,,,,,Disambiguate v1.0
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Manta,Computational Tool,,,,,,Manta
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Pindel,Computational Tool,,,,,,Pindel
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Variant Effect Predictor (VEP),Computational Tool,,,,,,Variant Effect Predictor (VEP)
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,GenVisR,Computational Tool,,,,,,GenVisR
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Xenosplit,Computational Tool,,,,,,Xenosplit
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,PartekFlow,Computational Tool,,,,,,PartekFlow
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Cell Ranger,Computational Tool,,,,,,Cell Ranger
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Seurat,Computational Tool,,,,,,Seurat
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,inferCNV,Computational Tool,,,,,,inferCNV
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,UPhyloplot2,Computational Tool,,,,,,UPhyloplot2
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,S462TY,Cell Line,,,,,,S462TY
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,ST8814,Cell Line,,,,,,ST8814
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.85,cell_line,Normal human Schwann cells (HSC),Cell Line,,,,,,Normal human Schwann cells (HSC)
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,HISAT2 version 2.2.1,Computational Tool,,,,,,HISAT2 version 2.2.1
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,StringTie version 2.2.1,Computational Tool,,,,,,StringTie version 2.2.1
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,DEGseq version 1.48.0,Computational Tool,,,,,,DEGseq version 1.48.0
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,ClusterProfiler version 4.2.2,Computational Tool,,,,,,ClusterProfiler version 4.2.2
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,STRING version 11.5,Computational Tool,,,,,,STRING version 11.5
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,FlowJo™ software v10.8,Computational Tool,,,,,,FlowJo™ software v10.8
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,Seahorse Wave Pro software,Computational Tool,,,,,,Seahorse Wave Pro software
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,GraphPad Prism version 9,Computational Tool,,,,,,GraphPad Prism version 9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.8,computational_tool,FASTQC,Computational Tool,,,,,,FASTQC
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,Agilent Tapestation 4200,Computational Tool,,,,,,Agilent Tapestation 4200
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.95,computational_tool,Varsome Clinical Software v.12.3.2,Computational Tool,,,,,,Varsome Clinical Software v.12.3.2
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,computational_tool,Plotly v4.9.3,Computational Tool,,,,,,Plotly v4.9.3
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,CNVKit version 0.9.11,Computational Tool,,,,,,CNVKit version 0.9.11
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,computational_tool,ggplot2 v3.5.1,Computational Tool,,,,,,ggplot2 v3.5.1
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,GEPIA,Computational Tool,,,,,,GEPIA
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,Cluster Profiler v.4.0,Computational Tool,,,,,,Cluster Profiler v.4.0
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,computational_tool,UpSetR Version 1.4.0,Computational Tool,,,,,,UpSetR Version 1.4.0
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.95,clinical_assessment_tool,Distress Thermometer (DT),Clinical Assessment Tool,,,,,,Distress Thermometer (DT)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,clinical_assessment_tool,Children's Depression Inventory (CDI-S),Clinical Assessment Tool,,,,,,Children's Depression Inventory (CDI-S)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,clinical_assessment_tool,Children's Depression Inventory Parent Version (CDI-P),Clinical Assessment Tool,,,,,,Children's Depression Inventory Parent Version (CDI-P)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,clinical_assessment_tool,Brief Symptom Inventory 18 (BSI-18),Clinical Assessment Tool,,,,,,Brief Symptom Inventory 18 (BSI-18)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,clinical_assessment_tool,Lansky Score,Clinical Assessment Tool,,,,,,Lansky Score
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,clinical_assessment_tool,Karnofsky Score,Clinical Assessment Tool,,,,,,Karnofsky Score
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.8,clinical_assessment_tool,Distress Thermometer Acceptability and Feasibility Scales,Clinical Assessment Tool,,,,,,Distress Thermometer Acceptability and Feasibility Scales
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,cell_line,T265,Cell Line,,,,,,T265
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,cell_line,NSF1,Cell Line,,,,,,NSF1
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,cell_line,B8 fibroblasts,Cell Line,,,,,,B8 fibroblasts
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,computational_tool,MATLAB® version R2007a,Computational Tool,,,,,,MATLAB® version R2007a
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,cell_line,STS26T,Cell Line,,,,,,STS26T
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,cell_line,S462,Cell Line,,,,,,S462
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,SynergyFinder,Computational Tool,,,,,,SynergyFinder
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,FlowJo v10,Computational Tool,,,,,,FlowJo v10
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,CIBERSORT,Computational Tool,,,,,,CIBERSORT
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,cell_line,ipNF05.5,Cell Line,,,,,,ipNF05.5
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,cell_line,95.6,Cell Line,,,,,,95.6
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,cell_line,ipn02.3,Cell Line,,,,,,ipn02.3
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,cell_line,ST88-14,Cell Line,,,,,,ST88-14
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,cell_line,S462,Cell Line,,,,,,S462
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,cell_line,NF90-8,Cell Line,,,,,,NF90-8
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,patient_derived_model,RHT-92,Patient-Derived Model,,,,,,RHT-92
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,animal_model,Nf1 flox/flox-;Postn-Cre,Animal Model,,,,,,Nf1 flox/flox-;Postn-Cre
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,animal_model,Nf1-Arf flox/flox ;Postn-Cre,Animal Model,,,,,,Nf1-Arf flox/flox ;Postn-Cre
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,computational_tool,ImageJ (v1.48),Computational Tool,,,,,,ImageJ (v1.48)
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,computational_tool,HALO (Indica Labs),Computational Tool,,,,,,HALO (Indica Labs)
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,computational_tool,Aperio Image Analysis (Leica Biosystems),Computational Tool,,,,,,Aperio Image Analysis (Leica Biosystems)
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.95,clinical_assessment_tool,PlexiQoL,Clinical Assessment Tool,,,,,,PlexiQoL
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,clinical_assessment_tool,Nottingham Health Profile,Clinical Assessment Tool,,,,,,Nottingham Health Profile
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,clinical_assessment_tool,Short Form-36,Clinical Assessment Tool,,,,,,Short Form-36
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,cell_line,"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)",Cell Line,,,,,,"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)"
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,cell_line,Mouse merlin-null schwannoma cells,Cell Line,,,,,,Mouse merlin-null schwannoma cells
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,animal_model,Nf2 flox2/flox2 mice,Animal Model,,,,,,Nf2 flox2/flox2 mice
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,computational_tool,XF96 Extracellular Flux Analyzer (Agilent Technologies),Computational Tool,,,,,,XF96 Extracellular Flux Analyzer (Agilent Technologies)
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.85,clinical_assessment_tool,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,Clinical Assessment Tool,,,,,,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.9,clinical_assessment_tool,Impact of Pediatric Illness (IPI) Scale,Clinical Assessment Tool,,,,,,Impact of Pediatric Illness (IPI) Scale
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.8,clinical_assessment_tool,STIR MRI,Clinical Assessment Tool,,,,,,STIR MRI
